Back to GetFilings.com
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-K
FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
---------------------------------
/x/ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended FEBRUARY 28, 2001
OR
/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Commission File No. 0-12991
THE LANGER BIOMECHANICS GROUP, INC.
------------------------------------------------------------------------------
(Exact name of Registrant as specified in its charter)
NEW YORK 11-2239561
---------------- -----------------
(State or other jurisdiction (I.R.S. employer
of incorporation or organization) identification number)
450 COMMACK ROAD, DEER PARK, NEW YORK 11729
--------------------------------------------------
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: (631) 667-1200
Securities registered pursuant to Section 12(b) of the Act: NONE
Securities registered pursuant to Section 12(g) of the Act:
COMMON STOCK, PAR VALUE $.02 PER SHARE
-----------------------------------------------------------
Title of Class
* * * * * * * * * * *
Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
YES x NO
---- ----
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of Registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. ( )
As of May 15, 2001 the aggregate market value of voting stock held by
non-affiliates of the Registrant was $6,152,707, as computed by reference to the
average bid and ask prices of the stock (4.48) multiplied by the number of
shares of voting stock outstanding on May 15, 2001 held by non-affiliates
(1,373,372).
Indicate the number of shares outstanding of each of the Registrant's classes of
common stock as of May 15, 2001.
CLASS OF COMMON STOCK OUTSTANDING AT MAY 15, 2001
- --------------------- ---------------------------
Common Stock, par value 4,181,922 shares
$.02 per share
DOCUMENTS INCORPORATED BY REFERENCE
Not applicable.
2
PART I
ITEM 1. BUSINESS
GENERAL
The Langer Biomechanics Group, Inc. (or the "Company") is engaged in the design,
manufacture and marketing of foot and gait-related biomechanical products. The
Company's largest product line, custom-made, prescription orthotic devices,
accounted for approximately 85% of revenues for the fiscal year ended February
28, 2001. Foot orthoses are contoured molds made from plastic, graphite, leather
or composite materials, which are placed in patients' shoes to (i) correct or
mitigate abnormalities in their gait and (ii) relieve symptoms associated with
foot or postural malalignment. These devices function by maintaining the proper
relationships between a patient's forefoot, rearfoot, leg and horizontal walking
surface. To the Company's knowledge, it has the greatest overall unit volume and
revenue in the custom foot orthoses industry. The Company's customers are
primarily podiatrists, and also include orthopedists, physical therapists and
Orthotic & Prosthetic ("O&P") centers.
In addition to its line of orthotics products, the Company has developed
and markets a number of other products that help treat biomechanical medical
problems related to feet and gait, including PPT-Registered Trademark- Medical
Grade Soft Tissue Supplement and CRS-Registered Trademark- Pediatric Counter
Rotation Splint.
BACKGROUND AND RECENT DEVELOPMENTS
Since its formation under the laws of the state of New York in 1971,
the Company has engaged in activities relating to the application of scientific
and quantitative methods for the diagnosis and treatment of foot and
gait-related problems. To date, the majority of the Company's revenues have been
derived from the sale of prescription biomechanical foot orthotic devices to
health care practitioners in the field of podiatric biomechanics. Podiatric
biomechanics deals essentially with the structure and function of segments of
the feet as they relate to each other and to the function of the legs, hips and
spine.
The Company has also endeavored to manufacture and market complementary
products relating to locomotor dysfunctions. Building on its experience in
treating disorders associated with the biomechanics of the foot and leg, the
Company has directed efforts towards producing therapeutic products which can
treat and improve patients' motor capabilities, biomechanical alignment and
function.
Export and foreign sales constituted approximately 36%, 34% and 26%
of revenues for the fiscal years ended February 28, 2001, and February 29,
2000 and February 28, 1999, respectively.
Effective February 13, 2001, Andrew H. Meyers, Greg Nelson and
Langer Partners LLC, and its designees ("Offerors"), acquired a controlling
interest in the Company when they purchased 1,362,509 validly tendered shares
of the Company at $1.525 per share, or approximately 51% of the then
outstanding common stock of the Company, under the terms of a December 27,
2000 Tender Offer Agreement ( the "Tender"), under which the Offerors offered
to purchase up to 75% of the Company's common stock. In order to provide the
Company with adequate equity to maintain the Company's compliance with the
listing requirements of the NASDAQ small cap market and to enable the Company
to finance its ongoing operations as well as potentially take advantages of
opportunities in the market place, in order to induce the Offerors to enter
into ther Tender Offer Agreement, pursuant to its terms, the Offerors were
granted 180 day options to purchase up to 1,400,000 shares of the Company's
common stock, with an initial exercise price of $1.525 per share, rising up
to $1.60 per share (the "Options"). These options have been recorded as a
non-cash dividend of $3,206,000, the fair market value of the Option on the
date of grant. Upon the closing of the Tender, the Board of Directors of the
Company resigned in favor of Andrew H. Meyers (President and Chief Executive
Officer), Burtt Ehrlich (Chairman of the Board), Jonathan R. Foster, Greg
Nelson and Arthur Goldstein, and the Company issued a total of 120,000
options to the four new outside members of the Board of Directors in
connection with their services on members of the Board.
In connection with the Tender and the resultant change in control, the
Company recorded costs and expenses of approximately $1,008,000. Please refer to
Management's Discussion and Analysis for a further discussion of these charges.
New management intends to expand the Company's business through
internal growth and acquisitions of companies in the medical device area in
the United States and Europe. Depending upon the opportunities available, the
3
Company may seek additional debt or equity financing. No assurances can be made
that the Company will find or consummate such additional financing on terms
acceptable to the Company.
As part of the change in control, new management determined that the
Company required additional cash to potentially take advantage of opportunities
in the marketplace. On February 13, 2001, three Directors of the Company
purchased 147,541 restricted shares at $1.525 for total proceeds of $225,000. On
May 11, 2001, the Offerors fully exercised the Options at $1.525 per share for
$2,135,0000, which was invested in the Company. Andrew H. Meyers converted an
existing $500,000 loan plus accrued interest as partial proceeds toward the
exercise of this Option. Prior to the exercise of this Option, the Company's net
worth dropped below the minimum required levels for listing on NASDAQ. This
shortfall has been fully remedied through the exercise of this Option and
management anticipates that the Company will continue to meet the NASDAQ listing
requirements.
CUSTOM ORTHOTIC DEVICES
During the twelve months ended February 28, 2001, Langer's sales of
custom biomechanical orthotic devices totaled $9,906,000, compared to $9,305,000
for the twelve months ended February 29, 2000. Increased revenue resulted from
increased unit volume in both the Company's domestic operations and the United
Kingdom subsidiary.
Biomechanical orthotic devices help provide near normal function by
maintaining the angular anatomical relationships between the patient's forefoot,
rearfoot, leg and horizontal walking surface. This is achieved by the inherent
contours of the neutral position shell of the device and by the angled posts on
the front and/or rear ends that cause the orthotic device to move into specific
positions at specific times during the gait cycle. Accordingly, muscle action is
enhanced and the efficiency and smoothness of weight stress transmission through
the feet and legs is improved. The result is a reduction of abnormal motion
without total restriction of normal motion and an increase in foot and leg
stability. Foot problems may be alleviated or eliminated, as may leg and back
fatigue caused by improper muscle use. The formation and further growth of
excrescences (e.g., corns, calluses, bunions) may be prevented, decreased in
size or eliminated. Biomechanical orthotic devices can be fabricated with
different functional capabilities and from various materials, depending upon the
requirements of the patient.
The Company has designed orthotic devices to address the needs of
particular segments of the market. For example, the general interest in physical
fitness has resulted in demand for orthotic devices and it has heightened the
awareness of the importance of proper foot function and foot care. To address
this segment of the market, the Company manufactures an extensive line of
orthotics called Sporthotics-Registered Trademark-, designed for the specific
needs of runners and other sport-specific athletes, including football,
basketball and tennis players. Langer offers many specialized products
including: Healthflex-Registered Trademark- (designed for the needs of aerobic
dance, walking and exercise enthusiasts), DesignLine-Registered Trademark- (a
functional orthotic designed to fit into dress shoes, such as high fashion shoes
and loafers which cannot accommodate a full-size orthotic), DressFlex-Registered
Trademark- (a unique patented proprietary device for use in women's high-heeled
shoes.)
While sales were primarily made to practitioners within the United
States, the Company also sold its orthotic products in approximately thirty-two
foreign countries. No single orthotic customer presently accounts for more than
1% of the Company's annual sales. The primary market for custom orthotic devices
is podiatrists who prescribe such devices for their patients. There are
approximately 14,000 practitioners of podiatry licensed in the United States.
Orthotic devices are also sold to other health care professionals, such as
orthopedists, physical therapists and orthotists/prosthetists engaged in the
treatment of the foot and lower extremity.
Langer makes orthotic devices in the Company's three facilities in Deer
Park, New York; Brea, California; and Stoke-on-Trent, England. The prescribing
practitioner furnishes plaster impression casts of the patient's feet and
necessary clinical information on an appropriate prescription order form. The
cost of the device to the patient is typically included by the practitioner as
part of his fee for treatment. The Company does not sell the devices directly to
the user-patient. In addition to its six-month warranty, an individual may
purchase an optional "Protect Program" extended warranty. Under the program, the
Company will repair or replace the orthotics at no charge, or at a reduced
charge, during the first 24 months following sale.
4
Another custom-made product line called "FirstChoice" was introduced in
fiscal 1995 in order to address price-sensitive market areas, including managed
care organizations. The product offering is limited to several basic products
and has flat rate pricing. The manufacturing and service areas are also limited
in order to reduce costs.
In 2000, Langer launched its first prefabricated foot orthoses, called
Contours-TM-. When cost is an issue for the patient, Contours provide an
off-the-shelf option for practitioners treating patients with certain foot
conditions. These prefabricated foot orthoses require no special casting by the
practitioner and are sold to practitioners through Langer and its distributors.
While the Company obtains a number of its fabrication materials from single
sources, it has not experienced any significant shortages other than occasional
backorders. In most cases, any needed materials can usually be obtained from an
alternate distributor.
The Company believes that a relatively small percentage of custom
orthotic devices continue to be made by practitioners in their own offices or
laboratories. The vast majority of the market is serviced by professional
laboratories based on casts and prescriptions furnished by practitioners. There
are several other custom orthotic laboratories that are national in scope which
the Company believes hold approximately a combined 40% to 45% of the overall
custom market. The remainder of the market is fragmented among smaller regional
and local facilities.
PPT-REGISTERED TRADEMARK- PRODUCTS
PPT is a medical grade soft tissue cushioning material with a high
density, open-celled urethane foam structure. PPT, a registered trademark of the
Company, is manufactured, pursuant to an agreement, for the Company by a large
industrial manufacturing company. This company manufactures urethane foam
materials of which PPT is a derivative. Pursuant to the agreement, the Company
has the exclusive worldwide rights to serve footcare, orthopedic and related
medical markets with such materials.
The Company has developed and sells a variety of products fabricated
from PPT including molded insoles, components for orthotic devices, laminated
sheets, and diabetic products. Some manufacturing operations associated with
these products are performed by outside vendors.
Sales of PPT products for the twelve months ended February 28, 2001 were
$1,240,000 versus $1,303,000 in the prior fiscal year. The decrease is primarily
attributable to lower sales to domestic distributors.
In 1993, the Company introduced a new generation of PPT, which
independent tests show to have improved properties over competitive materials.
The essential function of PPT and other soft tissue supplements is to provide
protection against forces of pressure, shock and shear. The Company believes
that PPT's characteristics make it a superior product in its field. PPT has a
superior "memory" that enables it to return to its original shape faster and
more accurately than other materials used for similar purposes. PPT is also
odorless and non-sensitizing to the skin, and has a porosity that helps the skin
to remain dry, cool and comfortable. These factors are especially important in
sports medicine applications.
Besides podiatric use, PPT is suitable for other orthopedic and
medical-related uses such as liners for braces and prosthetics, as shock
absorbers and generally in devices used in sports and physical therapy. The
company is in the process of expanding its PPT product offering to include shoe
inserts and braces marketing as PPTGel-TM-.
The Company has awarded exclusive distribution arrangements to certain
leading distributors serving selected end-use markets in the United States and
other countries. The Company sells direct to practitioners in non-exclusive
markets.
The market for soft tissue supplements is highly competitive. Brand
products as well as commodity type foam rubber are all widely used. Brand name
products include Spenco, Sorbothane, medical-grade Poron, and DCS. The remainder
of the market is fragmented. The Company competes directly with one other
manufacturer of cellular urethane foam.
5
MARKETING
The Company utilizes field sales representatives, targeting
multi-practitioner facilities, in addition to trade shows, advertising, direct
mail, educational sponsorships, public relations and maintenance marketing. The
Company continues to emphasize customer service by maintaining a staff of
customer service representatives at each of its facilities.
The Company continues its focus on providing the education and training
for healthcare practitioners who treat biomechanical problems of the lower
extremity through seminar and in-service programs. A comprehensive program is
offered in biomechanics, gait analysis and the cost-effectiveness of orthotic
therapy.
Management promotes awareness of orthotics through marketing and
operational initiatives. A Volume Incentive Program ("VIP") along with practice
building assistance is oriented toward helping practitioners expand the orthotic
components of their practices and relationship building with Langer's customer
base.
RESEARCH AND DEVELOPMENT
As of March 1, 1999, the Company established a Product Development
department to explore new applications for existing products and ensure that the
Company remains on the cutting edge of orthotic therapy. Research and
development costs incurred during the twelve months ended February 28, 2001 were
$252,000 compared to $149,000 in the prior fiscal year. This increase is
principally due to increased consulting expenses and costs associated with
potential new product introductions.
PATENTS AND TRADEMARKS
The Company holds 13 patents, 94 trademarks and 9 copyrights. These
patents and trademarks are held in 12 countries, including the United States.
The Company has exclusive licenses to three types of orthotic devices which are
patented in the United States and several foreign countries. In addition,
patents have also been granted to a third party in the United States and
numerous foreign countries with respect to the CRS (as to which the Company has
exclusive marketing rights). Loss of patent protection could have an adverse
effect on the Company's business by permitting competitors to utilize techniques
developed by the Company.
GOVERNMENTAL REGULATION
Rules of the Food and Drug Administration ("FDA") may from time to time
require the submission of a 510(k) notification of intent to market certain
products. Upon submission of a 510(k), the FDA may determine the product to be
substantially equivalent to products previously marketed in interstate commerce.
The Company is not aware of any requirements to file any 510(k) notifications.
EMPLOYEES
At March 1, 2001, the Company had 144 employees, of which 76 were
located in Deer Park, New York, 38 in Brea, California, and 30 in
Stoke-on-Trent, England. The employees are not represented by a union.
CONSULTANTS AND FIELD EVALUATION FORCE
The Company has oral or written agreements with three medical
specialists with respect to their providing professional consultative services
to the Company in their areas of specialization. Two of the consultants are on
the faculties of podiatric medicine colleges in the United States.
The consultants test and evaluate the Company's products, act as speakers
for the Company at symposiums and professional meetings, generally participate
in the development of the Company's products and services and disseminate
information about them. The Company also relies on practitioners in various
parts of the country to act as field evaluators of the Company's products.
6
SEASONALITY
Revenue derived from the Company's sale of orthotic devices, a
substantial portion of the Company's operations, has historically been
significantly higher in the warmer months of the year.
ITEM 2. PROPERTIES
The Company's executive offices, and its primary manufacturing
facilities, are located in Deer Park, New York. The Deer Park facility is
leased through July 31, 2005, with a four year extension option, and with
monthly lease payments averaging $25,181. The Company also leases space in
Brea, California (manufacturing facility) which principally expires on
December 31, 2001, and with aggregate monthly lease payments of $9,205. The
Company's United Kingdom subsidiary has a facility in Stoke-on-Trent, England
which is leased through August 2004, with a five year extension option, with
quarterly lease payments of $9,500 (at the current exchange rate). The
Company believes that its manufacturing facilities are suitable and adequate
and provide the productive capacity necessary for its current and reasonably
foreseeable future manufacturing needs. The Company believes that while these
manufacturing facilities are being adequately utilized, they could be more
fully utilized (e.g. with extended night shift operations) should this become
necessary.
ITEM 3. LEGAL PROCEEDINGS
None.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None.
7
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
PRICE RANGE OF COMMON STOCK
The Registrant's common stock, par value $.02 per share ("Common
Stock"), is traded on the over-the-counter market with quotations reported on
the National Association of Securities Dealers Automated Quotation System
(NASDAQ) under the symbol GAIT. The following table sets forth the high and low
closing bid prices for the Common Stock for the fiscal years ended February 28,
2001 and February 29, 2000. The NASDAQ quotations represent prices between
dealers, do not include retail markups, markdowns or commissions, and may not
represent actual transactions.
TWELVE MONTHS ENDED FEBRUARY 28, 2001 HIGH LOW
- ------------------------------------- -------- -------
1st quarter 1-3/4 1-11/16
2nd quarter 1-10/16 1-1/2
3rd quarter 1-11/16 1-1/4
4th quarter 5-1/8 1.00
TWELVE MONTHS ENDED FEBRUARY 29, 2000 HIGH LOW
- ------------------------------------- -------- -------
1st quarter 2 1-1/4
2nd quarter 1-13/16 1-3/8
3rd quarter 2 1-5/8
4th quarter 1-15/16 1-11/16
Closing bid and ask prices on May 23, 2001 were $4.45 and $4.15,
respectively. On February 28, 2001, there were approximately 300 holders of
record of the Common Stock. However, this figure is exclusive of all owners
whose stock is held beneficially or in "street" name. Based on information
supplied by various securities dealers, the Company believes that there are in
excess of 650 shareholders in total, including holders of record as well as
those whose shares are beneficially held.
DIVIDEND HISTORY AND POLICY
The Registrant has never paid cash dividends on its Common Stock and
anticipates that, for the foreseeable future, it will follow a policy of
retaining earnings to finance the expansion and development of its business. In
any event, future dividend policy will depend upon the Company's earnings,
financial condition, working capital requirements and other factors.
8
ITEM 6. SELECTED FINANCIAL DATA
(In thousands, except for per share data)
Fiscal Year Ended:
-----------------------------------------------------
(In thousands, except for per share data)
Feb. 28, Feb. 29, Feb. 28, Feb. 28, Feb. 28,
2001 2000 1999 1998 1997
-------- -------- -------- -------- --------
Consolidated Statement of Operations:
Net sales $11,642 $11,145 $10,307 $10,156 $10,515
Change in control and restructuring expenses (1,008) -- -- -- --
Operating (loss) profit (1,504) (356) 105 316 271
(Loss) income before income taxes (1,502) (337) 329 370 331
Provision for (benefit from) income taxes 4 (2) 25 5 28
Net (loss) income (1,506) (335) 304 365 303
Net income (loss) per common share:
Basic (0.58) (0.13) 0.12 0.14 0.12
Diluted (0.58) (0.13) 0.12 0.14 0.11
Weighted average number of common shares:
Basic 2,583 2,571 2,584 2,585 2,583
Diluted 2,583 2,571 2,607 2,658 2,666
Cash dividends per share -- -- -- -- -
Consolidated Balance Sheets:
Feb. 28, Feb. 29, Feb. 28, Feb. 28, Feb. 28,
2001 2000 1999 1998 1997
-------- -------- -------- -------- --------
Working Capital
757 1,715 2,423 2,090 2,050
Total Assets 4,554 4,738 5,125 4,848 4,445
Long-term Liabilities
(excluding current maturities) 126 277 305 375 444
Stockholders' Equity 1,599 2,536 2,934 2,663 2,291
9
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
CHANGE IN CONTROL:
Effective February 13, 2001, Andrew H. Meyers, Greg Nelson and
Langer Partners LLC, and its designees ("Offerors"), acquired a controlling
interest in the Company when they purchased 1,362,509 validly tendered shares
of the Company at $1.525 per share, or approximately 51% of the then
outstanding common stock of the Company, under the terms of a December 27,
2000 Tender Offer Agreement ( the "Tender"). Pursuant to the terms of the
Tender offer Agreement, the Offerors were granted an 180 day option to
purchase up to 1,400,000 shares of the Company's common stock, with an
initial exercise price of $1.525 per share, rising up to $1.60 per share (the
"Options"). This Option has been recorded as a non-cash dividend of
$3,206,000, the fair market value of the Option on the date of grant. Upon
the closing of the Tender, the Board of Directors of the Company resigned in
favor of Andrew H. Meyers (President and Chief Executive Officer), Burtt
Ehrlich (Chairman of the Board), Jonathan R. Foster, Greg Nelson and Arthur
Goldstein. In conjunction with the Tender, the Company issued a total of
120,000 options to the four new outside members of the Board of Directors.
In connection with the Tender and the resultant change in control, the
Company recorded expenses of approximately $1,008,000, which included legal fees
of $263,000, valuation and consultant fees of $95,000, severance and related
expenses for terminated employees and executives of approximately $236,000, and
other costs directly attributable to the change in control of approximately
$169,000. Additionally, as part of the change in control, a consulting firm,
which was owned by the principal shareholder of Langer Partners LLC was granted
100,000 fully vested stock options with an exercise price of $1.525 per share.
Accordingly, the Company immediately recognized the fair value of the option of
$245,000 as consulting fees associated with these options.
In connection with the Tender, the Company's existing revolving credit
facility with a bank was terminated. In order to provide for the Company's
short-term cash needs, in February 2001, the Company' Chief Executive Officer
loaned the Company $500,000. As part of the change in control, new management
determined that the Company required additional cash to potentially take
advantage of opportunities in the marketplace. On February 13, 2001, three
Directors of the Company purchased 147,541 restricted shares at $1.525 for total
proceeds of $225,000. On May 11, 2001, the Offerors fully exercised the Options
at $1.525 per share for $2,135,0000, which was invested in the Company. Andrew
H. Meyers, CEO, converted the $500,000 loan plus accrued interest as partial
proceeds toward the exercise of this Option. Prior to the exercise of this
Option, the Company's net worth dropped below the minimum required levels for
listing on NASDAQ. This shortfall has been fully remedied through the exercise
of this Option and management anticipates that the Company will continue to meet
the NASDAQ listing requirements.
STATEMENTS OF OPERATIONS:
The Company's net sales of $11,642,000 for the twelve months ended
February 28, 2001 were 4.5 percent above net sales of $11,145,000 for the twelve
months ended February 29, 2000. Net sales in fiscal 2000 were 8.1 percent above
net sales of $10,307,000 for the twelve months ended February 28, 1999.
Sales of orthotic products, which accounted for 85 percent of the
Company's fiscal 2001 sales, increased by approximately $601,000 or 6.5 percent
to approximately $9,906,000 in the most recent twelve-month period. The
increased sales of orthotic products is principally due to increased unit volume
resulting from increased marketing activities in both the Company's domestic
operations as well as its United Kingdom operations. Sales of orthotic products
in fiscal 2000 increased by $784,000 or 9.2 percent to $9,305,000 from fiscal
1999. Increased revenue resulted from increased unit volume resulting from
increased marketing activities in both the Company's domestic operations as well
as its United Kingdom operations.
Sales of PPT (the Company's soft tissue supplement material) for the
recent twelve months were $1,240,000, which decreased by $63,000 or 4.8 percent
from sales in the prior fiscal year. The decrease in PPT sales is principally
due to lower sales to domestic distributors. For the year ended February 29,
2000, sales were $1,303,000, representing a 2.7 percent increase from the prior
year. The increase in PPT sales over the prior fiscal year was principally due
to increased European sales.
10
Gross profit (net sales less cost of sales) as a percentage of sales
decreased from 35.5 percent for the twelve months ended February 29, 2000 to
32.5 percent for the recent twelve-month period. The decrease in the gross
profit percentage was primarily the result of increased shipping expenses, a
provision for obsolete and slow moving inventory of approximately $138,000 and
lower productivity principally attributable to an increase in direct labor
trainees as a percentage of the total direct labor workforce. Gross profit as a
percentage of sales decreased from 36.4 percent for the twelve months ended
February 28, 1999 to 35.5 percent for the year-end February 29, 2000. The
decreased gross profit percentage was primarily the result of increased overhead
costs.
For the current fiscal year, selling expenses increased by $305,000 (or
17.8 percent), and general and administrative expenses decreased by $448,000 (or
18.2 percent), compared to the prior twelve-month period. The increase in
selling expenses is primarily due to increased salary and travel expenses and
increased promotional activities focused on increasing market share and future
sales. The decrease in general and administrative expenses is principally due to
decreased professional fees and travel expenses. For the twelve-month period
ended February 29, 2000, selling expenses increased by $308,000, and general and
administrative expenses increased by $214,000, compared to the prior
twelve-month period. The increase in selling expenses was driven by increased
salary and travel expenses and increased commissions associated with the
increased sales and increased promotional activities. The increase in general
and administrative expenses was principally due to increased professional fees
and travel expenses.
Research and development costs incurred during the twelve months ended
February 28, 2001 were $252,000 compared to $149,000 in the prior fiscal year.
This increase is principally due to increased consulting expenses and costs
associated with potential new product introductions. The Company incurred no
research and development expenses in fiscal 1999.
As discussed above, the Company incurred approximately $1,008,000 of
change in control and restructuring costs during fiscal 2001.
Other income for fiscal 2001 decreased to ($2,000) from $19,000 in the
prior year principally due to decreased interest income of approximately $28,000
resulting from reduced cash balances for investment and increased interest
expense of approximately $13,000 on the installment note used to finance
equipment purchases in the prior year. Other income for fiscal year 2000 was
($11,000) as compared to $208,000 in the prior fiscal year. The significant
decrease is due to an insurance claim settlement received in 1999 for a fire at
the main production facility several years ago.
LIQUIDITY AND CAPITAL RESOURCES
Working capital as of February 28, 2001 decreased $958,000 to $757,000
from $1,715,000 at February 29, 2000 and cash balances at February 28, 2001 of
$869,000 were $49,000 below the prior year-end balance of $918,000. During the
past year, the working capital decreased as a result of the loss from
operations, the costs associated with the change-in-control discussed above, and
the purchase of the remaining 25% interest in the Company's Langer Biomechanics
Group (UK) Limited subsidiary for $80,000 cash and the issuance of 40,000 shares
from treasury. Additionally, the Company purchased approximately $80,000 of its
common stock in the open market.
In connection with the Tender, the Company's existing revolving
credit facility with a bank was terminated. In order to provide for the
Company's short-term cash needs, in February 2001, the Company's Chief
Executive Officer loaned the Company $500,000 evidenced by a promissory note,
bearing interest at prime plus 1%, which is due August 31, 2001, subject to
prepayment under certain conditions. Upon exercise of the Options on May 11,
2001, the principal amount of the loan, together with accrued interest in the
amount of $11,112 exchanged as partial consideration for the payment of the
shares of stock. On May 11, 2001, the Offerors fully exercised the Options at
$1.525 per share for $2,135,0000, which was invested in the Company.
At February 28, 2001, $81,458 was outstanding on an $115,000
installment note to finance the acquisition of certain machinery and equipment
in the prior year. As a result of the Tender, this note became due and payable
and accordingly, has been classified as current. This note was repaid in March
2001. The loan bore interest at 9.5% per annum and required 48 monthly payments
of $2,396.
11
Repurchases of the Company's common stock may be made from time to
time in the open market at prevailing prices or in privately negotiated
transactions, subject to available resources. The Company may also finance
acquisitions of other companies or product lines in the future from existing
cash balances and, from borrowings from institutional lenders, and/or the
public or private offerings of debt or equity securities. Management believes
that its existing cash balances, funds generated from operations and the
proceeds from the exercise of the Options discussed above will be adequate to
meet the Company's cash needs during the fiscal year ending February 28, 2002.
SEASONALITY
Revenue derived from the Company's sale of orthotic devices, a
substantial portion of the Company's operations, has historically been
significantly higher in the warmer months of the year.
INFLATION
The Company has in the past been able to increase the prices of its
products or reduce overhead costs sufficiently to offset the effects of
inflation on wages, materials and other expenses, and anticipates that it will
be able to continue to do so in the future.
RECENT PRONOUNCEMENTS OF THE FINANCIAL ACCOUNTING STANDARDS BOARD
In June 1998, the FASB issued SFAS No. 133, "Accounting for Derivative
Instruments and Hedging Activities" ("SFAS No. 133"), which requires that
derivative instruments be measured at fair value and recognized as assets or
liabilities in the Company's balance sheet. SFAS No.133( as amended by SFAS No.
138) is effective for all quarters of all fiscal years beginning after June 15,
2000. The Company is currently evaluating the effect that SFAS No. 133 will have
on the Company's consolidated financial statements.
CERTAIN FACTORS THAT MAY AFFECT FUTURE RESULTS
Information contained or incorporated by reference in the annual report
on Form 10-K and in other SEC filings by the Company contains "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995 which can be identified by the use of forward-looking terminology such
as "believes," "expects," "may," "will," "should," or "anticipates" or the
negative thereof, other variations thereon or comparable terminology, or by
discussions of strategy. No assurance can be given that future results covered
by the forward-looking statements will be achieved, and other factors could also
cause actual results to vary materially from the future results covered in such
forward-looking statements. Factors which might cause such a difference include,
but are not limited to, product demand, the impact of competitive products and
pricing and general business and economic conditions.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not applicable.
-
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Begins on the next page.
12
THE LANGER BIOMECHANICS GROUP, INC.
AND SUBSIDIARIES
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS AND SCHEDULE
FEBRUARY 28, 2001, FEBRUARY 29, 2000 AND FEBRUARY 28, 1999
PAGE
----
Independent Auditors' Report 14
Consolidated Financial Statements:
Consolidated Balance Sheets as of February 28, 2001 and February 29, 2000 15
Consolidated Statements of Operations for the years ended February 28, 2001,
February 29, 2000 and February 28,1999 16
Consolidated Statements of Stockholders' Equity for the years ended
February 28, 2001, February 29, 2000 and February 28, 1999 17
Consolidated Statements of Cash Flows for the years ended
February 28, 2001, February 29, 2000 and February 28, 1999 18
Notes to Consolidated Financial Statements 19 - 29
Consolidated Financial Statement Schedule II -
Valuation and Qualifying Accounts for the years ended
February 28, 2001, February 29, 2000 and February 28, 1999 30
All other schedules have been omitted because they are not applicable, not
required or the information is disclosed in the consolidated financial
statements, including the notes thereto.
13
INDEPENDENT AUDITORS' REPORT
To the Stockholders and Board of Directors of
The Langer Biomechanics Group, Inc. and Subsidiaries
We have audited the accompanying consolidated balance sheets of The Langer
Biomechanics Group, Inc. and subsidiaries (the "Company") as of February 28,
2001 and February 29, 2000, and the related consolidated statements of
operations, stockholders' equity and cash flows for each of the three years in
the period ended February 28, 2001. Our audits also included the consolidated
financial statement schedule listed in the foregoing index for the three years
in the period ended February 28, 2001. These consolidated financial statements
and financial statement schedule are the responsibility of the Company's
management. Our responsibility is to express an opinion on the consolidated
financial statements and financial statement schedule based on our audits.
We conducted our audits in accordance with auditing standards generally accepted
in the United States of America. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the consolidated financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by management, as well
as evaluating the overall consolidated financial statement presentation. We
believe that our audits provide a reasonable basis for our opinion.
In our opinion, such consolidated financial statements present fairly, in all
material respects, the financial position of the Company at February 28, 2001
and February 29, 2000, and the results of its operations and its cash flows for
each of the three years in the period ended February 28, 2001 in conformity with
accounting principles generally accepted in the United States of America. Also,
in our opinion, such consolidated financial statement schedule, when considered
in relation to the basic consolidated financial statements taken as a whole,
presents fairly, in all material respects, the information set forth therein.
Jericho, New York
May 14, 2001
14
THE LANGER BIOMECHANICS GROUP, INC.
AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
FEBRUARY 28, 2001 AND FEBRUARY 29, 2000
2001 2000
---- ----
Assets
Current assets:
Cash and cash equivalents $ 868,846 $ 918,115
Accounts receivable, net of allowance for
doubtful accounts of approximately
$58,000 in 2001 and $63,000 in 2000 1,542,464 1,316,530
Inventories, net (Note 4) 973,863 1,189,384
Prepaid expenses and other current receivables 200,839 215,580
------------ ------------
Total current assets 3,586,012 3,639,609
Property and equipment, net (Note 5) 683,501 945,270
Other Assets (Note 9) 284,706 153,312
------------ ------------
Total Assets (Note 13) $ 4,554,219 $ 4,738,191
============ ============
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $ 652,974 $ 580,057
Accrued liabilities(Note 6) 1,166,162 895,925
Current portion of long-term debt (Note 13) 581,458 28,750
Unearned revenue (Note 1) 428,133 420,221
------------ ------------
Total current liabilities 2,828,727 1,924,953
Accrued pension expense (Note 9) 13,118 82,910
Unearned revenue (Note 1) 104,381 104,380
Long-term debt (Note 13) -- 81,458
Deferred income taxes (Note 7) 8,662 8,167
------------ ------------
Total liabilities 2,954,888 2,201,868
------------ ------------
Commitments and Contingencies (Note 8)
Stockholders' equity (Note 10):
Common stock, $.02 par value. Authorized
10,000,000 shares; issued 2,849,022
shares in 2001 and 2,640,281 shares in 2000 56,981 52,806
Additional paid-in capital 10,086,555 6,325,880
Accumulated deficit (8,118,291) (3,405,904)
Accumulated other comprehensive loss (Note 9) (310,457) (300,266)
------------ ------------
1,714,788 2,672,516
Less treasury stock at cost, 67,100 shares in 2001
and 81,500 in 2000 (115,457) (136,193)
------------ ------------
Total stockholders' equity 1,599,331 2,536,323
------------ ------------
Total Liabilities and Stockholders' Equity $ 4,554,219 $ 4,738,191
============ ============
See accompanying notes to consolidated financial statements.
15
THE LANGER BIOMECHANICS GROUP, INC.
AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE YEARS ENDED FEBRUARY 28, 2001, FEBRUARY 29, 2000 AND FEBRUARY 28, 1999
2001 2000 1999
------------ ------------ ------------
Net sales (Note 11) $ 11,642,152 $ 11,145,054 $ 10,307,114
Cost of sales 7,862,998 7,186,446 6,557,200
------------ ------------ ------------
Gross profit 3,779,154 3,958,608 3,749,914
Selling expenses 2,011,390 1,706,879 1,399,339
Research and development expenses 252,345 148,710 --
General and administrative expenses 2,010,905 2,459,079 2,245,467
Change in control and restructuring expenses (Note 2) 1,008,081
------------ ------------ ------------
Operating (loss) income (1,503,567) (356,060) 105,108
------------ ------------ ------------
Other income (expense):
Interest income 3,440 31,032 43,958
Interest expense (20,062) (6,711) (11,303)
Minority interest 5,188 5,240 (16,030)
Other (Note 11) 13,141 (10,499) 208,070
------------ ------------ ------------
Other income (expense), net 1,707 19,062 224,695
------------ ------------ ------------
(Loss) income before income taxes (1,501,860) (336,998) 329,803
Provision for (benefit from) income taxes (Note 7) 4,527 (1,724) 25,313
------------ ------------ ------------
Net (loss) income $ (1,506,387) $ (335,274) $ 304,490
------------ ------------ ------------
Weighted average number of common shares used
in computation of net (loss) income per share:
Basic 2,582,615 2,571,004 2,584,336
Diluted 2,582,615 2,571,004 2,607,285
Net (loss) income per common share:
Basic $ (0.58) $ (0.13) $ 0.12
============ ============ ============
Diluted $ (0.58) $ (0.13) $ 0.12
============ ============ ============
See accompanying notes to consolidated financial statements.
16
THE LANGER BIOMECHANICS GROUP, INC AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
FOR THE YEARS ENDED FEBRUARY 28, 2001, FEBRUARY 29, 2000 AND FEBRUARY 28, 1999
Accumulated Other
Comprehensive Income
Common Stock (Loss)
------------------- ----------------------------
Additional Foreign Minimum
Treasury Paid-in Accumulated Currency Pension
Shares Amount Stock Capital Deficit Translation Liability
- ----------------------------------------------------------------------------------------------------------------------------
Balance at March 1, 1998 2,585,281 $51,706 $6,277,543 ($3,375,120) ($49,571) ($241,828)
Comprehensive income:
Net income for 1999 304,490
Foreign currency
adjustment 2,676
Minimum pension
liability
adjustment (10,476)
Total comprehensive
income
Treasury stock acquired ($39,350)
Issuance of stock 12,000 240 13,260
Exercise of stock options 1,000 20 761
- ----------------------------------------------------------------------------------------------------------------------------
Balance at February 28, 1999 2,598,281 51,966 (39,350) 6,291,564 (3,070,630) (46,895) (252,304)
Comprehensive income:
Net loss for 2000 (335,274)
Foreign currency
adjustment (612)
Minimum pension
liability
adjustment (455)
Total comprehensive
income
Treasury stock acquired (96,843)
Exercise of stock options 42,000 840 34,316
- ----------------------------------------------------------------------------------------------------------------------------
Balance at February 29, 2000 2,640,281 52,806 (136,193) 6,325,880 (3,405,904) (47,507) (252,759)
Comprehensive income:
Net loss for 2001 (1,506,387)
Foreign currency
adjustment (5,227)
Minimum pension
liability
adjustment (4,964)
Total comprehensive income
Issuance of stock 147,541 2,951 222,049
Issuance of shares from
treasury 100,949
Non-cash dividend 3,206,000 (3,206,000)
Treasury stock acquired (80,213)
Issuance of stock options
for consulting services 245,000
Exercise of stock options 61,200 1,224 87,626
- ----------------------------------------------------------------------------------------------------------------------------
Balance at February 28, 2001 2,849,022 $56,981 ($115,457) $10,086,555 ($8,118,291) ($52,734) ($257,723)
============================================================================================================================
Total
Comprehensive Stockholders'
Income Equity
- ----------------------------------------------------------------------
Balance at March 1, 1998 $2,662,730
Comprehensive income:
Net income for 1999 $304,490
Foreign currency
adjustment 2,676
Minimum pension
liability
adjustment (10,476)
----------
Total comprehensive
income $296,690 296,690
----------
Treasury stock acquired (39,350)
Issuance of stock 13,500
Exercise of stock options 781
---------
Balance at February 28, 1999 2,934,351
Comprehensive income:
Net loss for 2000 $(335,274)
Foreign currency
adjustment (612)
Minimum pension
liability
adjustment (455)
----------
Total comprehensive
income $(336,341) (336,341)
----------
Treasury stock acquired (96,843)
Exercise of stock options 35,156
---------
Balance at February 29, 2000 2,536,323
Comprehensive income:
Net loss for 2001 $(1,506,387)
Foreign currency
adjustment (5,227)
Minimum pension
liability
adjustment (4, 964)
----------
Total comprehensive income ($1,516,578) (1,516,578)
----------
Issuance of stock 225,000
Issuance of shares from
treasury 100,949
Non-cash dividend -
Treasury stock acquired (80,213)
Issuance of stock options
for consulting services 245,000
Exercise of stock options 88,850
----------
Balance at February 28, 2001 $1,599,331
==========
See accompanying notes to consolidated financial statements.
17
THE LANGER BIOMECHANICS GROUP, INC.
AND SUBSIDIARIES
CONSOLIDATED FINANCIAL STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED FEBRUARY 28, 2001, FEBRUARY 29, 2000 AND FEBRUARY 28, 1999
2001 2000 1999
------ ------ ------
Cash Flows From Operating Activities:
Net (loss) income $(1,506,387) $(335,274) $ 304,490
Adjustments to reconcile net (loss) income to net cash
(used in) provided by operating activities:
Deferred foreign tax provision (benefit) 976 3,028 (135)
Depreciation and amortization 301,902 301,469 213,536
Provision for doubtful accounts receivable 19,000 31,167 59,788
Issuance of stock options for consulting services 245,000 - -
Changes in operating assets and liabilities:
Accounts receivable (262,412) 44,089 (91,260)
Inventories 206,813 (158,572) 9,294
Prepaid expenses and other assets 26,106 (48,806) 152,831
Accounts payable and accrued liabilities 367,861 (43,490) 102,290
Net pension liability (73,844) (112,344) (28,041)
Unearned revenue 14,399 65,195 (79,468)
------------ ------------ -----------
Net cash (used in) provided by operating activites (660,586) (253,538) 643,325
------------ ------------ -----------
Cash Flows From Investing Activities -
Langer UK purchase (145,138) - -
Capital expenditures (49,381) (577,024) (107,146)
------------ ------------ -----------
Net cash used in investing activities (194,519) (577,024) (107,146)
------------ ------------ -----------
Cash Flows From Financing Activities:
Common stock options exercised 88,850 35,156 781
Issuance of common stock 260,810 - 13,500
Treasury stock acquired (80,213) (96,843) (39,350)
Proceeds from issuance of debt 500,000 115,000 -
Payments on debt (28,750) (4,792) -
Issuance of common stock-UK purchase 65,139 - -
------------ ------------ -----------
Net cash provided by (used in) financing activites 805,836 48,521 (25,069)
------------ ------------ -----------
Net (decrease) increase in cash and cash equivalents (49,269) (782,041) 511,110
Cash and cash equivalents at beginning of year 918,115 1,700,156 1,189,046
------------ ------------ -----------
Cash and cash equivalents at end of year $ 868,846 $ 918,115 $1,700,156
============ ============ ===========
Supplemental Disclosures of Cash Flow Information-
Cash paid during the year for:
Interest $17,663 $6,711 $ 11,303
============ ============ ===========
Income taxes $2,348 $8,500 $ 5,600
Non-cash Financing Activities- ============ ============ ===========
Issuance of stock options due to change in control $ 3,206,000 - -
============ ============ ===========
See accompanying notes to consolidated financial statements.
18
THE LANGER BIOMECHANICS GROUP, INC.
AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED FEBRUARY 28, 2001, FEBRUARY 29, 2000 AND FEBRUARY 28, 1999
(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(a) PRINCIPLES OF CONSOLIDATION
The accompanying consolidated financial statements include the accounts of
The Langer Biomechanics Group, Inc. and its subsidiaries (the "Company").
All significant intercompany transactions and balances have been eliminated
in consolidation.
(b) REVENUE RECOGNITION
Revenue from the sale of the Company's products is recognized at shipment.
Revenues derived from extended warranty contracts relating to sales of
orthotics are recorded as deferred revenue and recognized over the lives of
the contracts (24 months) on a straight-line basis.
(c) CASH EQUIVALENTS
For purposes of the statement of cash flows, the Company considers all
short-term, highly liquid investments purchased with a maturity of three
months or less to be cash equivalents (money market funds and short-term
commercial paper).
(d) INVENTORIES
Inventories are stated at the lower of cost or market. Cost is determined
using the first-in, first-out (FIFO) method.
(e) PROPERTY AND EQUIPMENT
Property and equipment is stated at cost less accumulated depreciation and
amortization. Depreciation and amortization are calculated using the
straight-line method. The lives on which depreciation and amortization are
computed are as follows:
Leasehold improvements Lesser of 5 years or life of lease
Machinery and equipment 5 - 10 years
Office equipment 3 - 10 years
Automobiles 3 - 5 years
The Company reviews long-lived assets and certain identifiable intangibles
whenever events or changes in circumstances indicate that the carrying
amount of an asset may not be recoverable. If the sum of expected future
cash flows (undiscounted and without interest charges) is less than the
carrying value of the asset, an impairment loss is recognized. Otherwise,
an impairment loss is not recognized.
19
(f) INCOME TAXES
The Company accounts for income taxes using an asset and liability method.
Under this method, deferred tax assets and liabilities are determined based
on differences between financial reporting and tax bases of assets and
liabilities and are measured using the enacted tax rates and laws that will
be in effect when the differences are expected to reverse. Income tax
expense (benefit) is the tax payable or refundable for the period plus or
minus the change during the period in deferred tax assets and liabilities.
(g) NET INCOME (LOSS) PER SHARE
Basic earnings per share are based on the weighted average number of shares
of common stock outstanding during the period. Diluted earnings per share
are based on the weighted average number of shares of common stock and
common stock equivalents (options and warrants) outstanding during the
period, except where the effect would be antidilutive, computed in
accordance with the treasury stock method.
(h) FOREIGN CURRENCY TRANSLATION
Assets and liabilities of the foreign subsidiary have been translated at
year-end exchange rates, while revenues and expenses have been translated
at average exchange rates in effect during the year. Resulting cumulative
translation adjustments have been recorded as a separate component of
accumulated other comprehensive loss.
(i) RECLASSIFICATIONS
Certain amounts in the prior years' financial statements have been
reclassified to conform to the current year's presentation.
(j) USE OF ESTIMATES
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those
estimates.
(k) FAIR VALUE OF FINANCIAL INSTRUMENTS
At February 28, 2001 and February 29, 2000, the carrying amount of the
Company's financial instruments, including cash and cash equivalents,
accounts receivable, accounts payable and accrued liabilities, approximated
fair value because of their short-term maturity. The carrying value of
long-term debt at February 29, 2000 also approximated fair value based on
borrowing rates currently available to the Company for debt with similar
terms.
(l) INTERNAL USE SOFTWARE
In accordance with Statement of Position 98-1, "Accounting for the Costs of
Computer Software Developed or Obtained for Internal Use", the Company
capitalizes internal-use software costs upon the completion of the
preliminary project stage and ceases capitalization when the software
project is substantially complete and ready for its intended use.
Capitalized costs are amortized on a straight-line basis over the estimated
useful life of the software, but in no event more than four years.
(m) RECENT PRONOUNCEMENTS OF THE FINANCIAL ACCOUNTING STANDARDS BOARD
In June 1998, the FASB issued SFAS No. 133, "Accounting for Derivative
Instruments and Hedging Activities" ("SFAS No. 133"), which requires that
derivative instruments be measured at fair value and recognized as assets
or liabilities in the Company's balance sheet. SFAS No. 133 (as amended by
SFAS No. 138) is effective for all
20
quarters of all fiscal years beginning after June 15, 2000. The Company is
currently evaluating the effect that SFAS No. 133 will have on the
Company's consolidated financial statements.
(2) CHANGE IN CONTROL AND RESTRUCTURING EXPENSES
Effective February 13, 2001, Andrew H. Meyers, Greg Nelson and Langer
Partners LLC, and its designees ("Offerors"), acquired a controlling interest
in the Company when they purchased 1,362,509 validly tendered shares of the
Company at $1.525 per share, or approximately 51% of the then outstanding
common stock of the Company, under the terms of a December 27, 2000 Tender
Offer Agreement ( the "Tender"), under which the Offerors offered to purchase
up to 75% of the Company's common stock. In order to provide the Company with
adequate equity to maintain the Company's compliance with the listing
requirements of the NASDAQ small cap market and to enable the Company to
finance its ongoing operations as well as potentially take advantages of
opportunities in the market place, in order to induce the Offerors to enter
into ther Tender Offer Agreement, pursuant to its terms, the Offerors were
granted 180 day options to purchase up to 1,400,000 shares of the Company's
common stock, with an initial exercise price of $1.525 per share, rising up
to $1.60 per share (the "Options"). These Options have been recorded as a
non-cash dividend of $3,206,000, the fair market value of the Option on the
date of grant. Upon the closing of the Tender, the Board of Directors of the
Company resigned in favor of Andrew H. Meyers (President and Chief Executive
Officer), Burtt Ehrlich (Chairman of the Board), Jonathan R. Foster, Greg
Nelson and Arthur Goldstein. The Company issued 30,000 non-qualified options
at $1.525 to each of the four new outside members of the Board of Directors
in connection with their service as members of the Board.
In connection with the Tender and the resultant change in control, the Company
recorded expenses of approximately $1,008,000, which included legal fees of
$263,000, valuation and consultant fees of $95,000, severance and related
expenses for terminated employees and executives of approximately $236,000, and
other costs directly attributable to the change in control of approximately
$169,000. As part of the change in control, a consulting firm, which is owned by
the sole manager and voting member of Langer Partners LLC, a principal
shareholder of the Company, was granted 100,000 fully vested stock options with
an exercise price of $1.525 per share. Accordingly, the Company immediately
recognized the fair value of the option of $245,000 as consulting fees
associated with these options.
Upon closing of the Tender and the resultant change in control, the Company's
existing revolving credit facility with a bank was terminated. In order to
provide for the Company's short-term cash needs, in February 2001, the
Company's Chief Executive Officer loaned the Company $500,000 (see note 13).
As part of the change in control, new management determined that the Company
required additional cash to potentially take advantage of opportunities in
the marketplace. On February 13, 2001, three Directors of the Company
purchased 147,541 restricted shares at $1.525 for total proceeds of $225,000.
On May 11, 2001, the Offerors fully exercised the Options at $1.525 per share
for $2,135,0000, which was invested in the Company. Andrew H. Meyers, CEO,
converted the $500,000 loan plus accrued interest as partial proceeds toward
the exercise of these Options.
(3) ACQUISITION
Effective April 5, 2000, the Company purchased the remaining 25% interest, which
it did not previously own, in its Langer Biomechanics Group (UK) Limited
subsidiary for $80,000 cash and the issuance of 40,000 shares of common stock
from treasury. Such shares were valued at $65,139, representing the market value
of the Company's common stock at the date of the transaction. The transaction
was accounted for as a purchase and the excess cost over the fair value of net
assets acquired of $145,993 is being amortized on a straight-line basis over a
ten-year period. Amortization expense for 2001 was $7,300. If the acquisition
were assumed to have occurred at the beginning of fiscal 2000, the impact on the
results of operations would not have been material.
(4) INVENTORIES
Inventories consist of the following at February 28, 2001 and February
29,2000:
2001 2000
------------- -------------
Raw materials $ 795,111 $ 762,282
Work-in-process 107,006 88,359
Finished goods 265,069 394,473
------------- -------------
Total inventories 1,167,186 1,245,114
Less allowance for obsolescence 193,323 55,730
------------- -------------
Net inventories $ 973,863 $ 1,189,384
============= =============
21
(5) PROPERTY AND EQUIPMENT
Property and equipment, at cost, is comprised of the following at February
28, 2001 and February 29, 2000:
2001 2000
------------- -------------
Leasehold improvements $ 584,708 $ 592,570
Machinery and equipment 953,395 949,091
Office equipment 2,182,760 2,168,645
Automobiles 39,750 34,712
------------- -------------
3,760,613 3,745,018
Less accumulated depreciation and amortization 3,077,112 2,799,748
------------- -------------
Property and equipment, net $ 683,501 $ 945,270
============= =============
(6) OTHER CURRENT LIABILITIES
Other current liabilities consist of the following at February 28, 2001 and
February 29, 2000:
2001 2000
------------- -------------
Accrued payroll and related payroll taxes $ 339,168 $ 303,452
Sales credits payable 105,405 104,134
Other 721,589 488,339
------------- -------------
Total other accrued liabilities $ 1,166,162 $ 895,925
============== =============
(7) INCOME TAXES
The provision for (benefit from) income taxes is comprised of the
following for the years ended February 28, 2001, February 29, 2000 and
February 28,1999:
2001 2000 L999
----------- ---------- -----------
Current:
Federal $ - $ 1,500 $ (2,500)
State 5,000 (7,200) 9,000
Foreign (1,774) 948 18,948
----------- ---------- -----------
3,226 (4,752) 25,448
Deferred - Foreign 1,301 3,028 (135)
----------- ---------- -----------
$ 4,527 $ (1,724) $ 25,313
=========== ========== ===========
As of February 28, 2001, the Company has net Federal tax operating loss
carryforwards of approximately $3,773,000, which may be applied against
future taxable income and expire from 2002 through 2013. The Company also
has available tax credit carryforwards of approximately $141,000.
22
The following is a summary of deferred tax assets and liabilities as of February
28, 2001 and February 29, 2000:
2001 2000
------------- -------------
Current deferred tax assets $ 202,389 $ 148,458
------------- -------------
Non-current:
Deferred tax assets 1,436,591 1,094,201
Deferred tax liability (8,662) (8,167)
------------- --------------
Non-current deferred tax assets, net 1,427,929 1,086,034
------------- -------------
Total deferred tax assets, net 1,630,318 1,234,492
Valuation allowance (1,638,980) (1,242,659)
------------- -------------
Net $ (8,662) $ (8,167)
============= ==============
The following is a summary of the domestic and foreign components of (loss)
income before taxes for the years ending February 28, 2001, February 29, 2000
and February 28, 1999:
2001 2000 1999
---------- --------- ----------
Domestic $(1,466,510) $(325,254) $ 262,792
Foreign (35,350) (11,744) 67,011
------------ ---------- ----------
$(1,501,860) $(336,998) $ 329,803
============ ========== ==========
The current deferred tax assets primarily relate to deferred revenue, inventory
and accounts receivable reserves, accrued pension and accrued vacation. The
non-current deferred tax assets are primarily composed of deferred revenue and
Federal net operating loss carryforwards. The non-current deferred tax liability
is primarily composed of excess tax depreciation over book depreciation and is
entirely related to foreign operations. The increase in the valuation allowance
during fiscal 2001 resulted from the creation of additional net operating loss
carryforwards not recognized for financial statement purposes. Future
utilization of these net operating loss carryforwards will be limited under
existing tax law due to the change in control of the Company (Note 2).
The Company's effective provision for income taxes differs from the Federal
statutory rate. The reasons for such differences are as follows:
FEBRUARY 28, FEBRUARY 29, FEBRUARY 28,
2001 2000 1999
------------------ ------------------ -------------------
AMOUNT % AMOUNT % AMOUNT %
------ ----- ------ ----- --------- -------
Provision at Federal
statutory rate $ (510,633) (34.0)% $(114,579) 34.0% $ 112,133 34.0%
Increase (decrease) in taxes
resulting from:
State income taxes, net of
Federal benefit 3,300 .2 (4,752) (1.4) 9,000 2.7
Foreign taxes 11,546 .8 7,969 2.3 18,813 5.7
(Use) creation of net operating
loss carryforwards 500,314 33.3 109,638 32.6 (114,633) (34.7)
----------- ------ --------- ------ --------- ------
Effective tax rate $ 4,527 .3% $ (1,724) (0.5)% $ 25,313 7.7%
=========== ====== =========== ========= ========= ======
23
(8) COMMITMENTS AND CONTINGENCIES
(a) LEASES
Certain of the Company's facilities and equipment are leased under
noncancellable operating leases. Rental expense amounted to $496,401,
$449,754 and $430,345 for the years ended February 28, 2001, February
29, 2000 and February 28, 1999, respectively.
The following is a schedule, by fiscal year, of future minimum rental
payments required under operating leases as of February 28, 2001:
FISCAL YEAR ENDING FEBRUARY: AMOUNT
--------------------------- --------------
2002 $ 463,232
2003 359,002
2004 351,506
2005 341,580
2006 192,522
-------------
Total $1,707,842
=============
(b) ROYALTIES
The Company has entered into a number of agreements with licensors,
consultants and suppliers, including:
1. An agreement with a licensor, which provides for the Company to
pay royalties of 15 percent, with a minimum annual royalty of
$25,000, on the net sales of a product named the Pediatric
Counter Rotation System.
2. Agreements with certain licensors, which provide for the Company
to pay royalties ranging from 2.5 percent to 15 percent on the
net sales of certain biomechanical devices.
3. An agreement with a licensor to pay a royalty of $.85 for every
positive mold used in the manufacture of custom orthotics
generated by the proprietary software developed by the licensor.
Additionally, the Company has an exclusive license expiring in
June 2001 with this licensor for the custom manufacture of
footbed products requiring an annual royalty of $42,500. The
Company has not manufactured any product under this license and
has notified the licensor that it will not renew its exclusive
license and has charged the remaining obligation of $14,167 to
restructuring expense.
Royalties under the above-mentioned agreements aggregated $79,138,
$34,285 and $34,095 for the years ended February 28, 2001, February
29, 2000 and February 28, 1999, respectively.
(9) PENSION PLAN AND 401(k) PLAN
The Company maintains a non-contributory defined benefit pension plan
covering substantially all employees. In 1986, the Company adopted an
amendment to the plan under which future benefit accruals to the plan will
cease (freezing of the maximum benefits available to employees as of July
30, 1986), other than those required by law. Previously accrued benefits
will remain in effect and will continue to vest under the original terms
of the plan.
The following table sets forth the Company's defined benefit plan status
at February 28, 2001 and February 29, 2000, determined by the plan's
actuary in accordance with Statement of Financial Accounting Standards
("SFAS") No. 87, "Employers' Accounting for Pensions", as amended by SFAS
No. 132:
24
2001 2000
------------- -------------
Projected benefit obligation $ (455,334) $ (438,900)
Plan assets at fair market value (primarily bond mutual funds) 442,216 355,990
------------- -------------
Projected benefit obligation in excess of plan assets (13,118) (82,910)
Unrecognized transition liability 135,693 143,484
Unrecognized net loss 257,723 252,759
Minimum additional liability (393,416) (396,243)
------------- -------------
Accrued pension cost $ (13,118) $ (82,910)
============= =============
Change in projected benefit obligation:
Projected benefit obligation, beginning of year $ (438,900) $ (413,708)
Interest cost (32,918) (31,028)
Benefits paid 19,053 7,627
Actuarial loss (2,569) (1,791)
------------- -------------
Projected benefit obligation, end of year $ (455,334) $ (438,900)
============= =============
Change in plan assets:
Fair value of plan assets, beginning of year $ 355,990 $ 257,244
Actual return on plan assets 13,515 3,480
Employer contribution 91,764 102,893
Benefits paid (19,053) (7,627)
-------------- -------------
Fair value of plan assets, end of year $ 442,216 $ 355,990
============= =============
Net periodic pension expense is comprised of the following components for the
years ended February 28, 2001, February 29, 2000 and February 28, 1999:
2001 2000 1999
-------------- ------------- --------------
Interest cost on projected benefit obligations $ 32,918 $ 31,028 $ 30,355
Expected return on plan assets (29,426) (22,866) (17,595)
Amortization of unrecognized transition liability 7,791 7,791 7,791
Recognized actuarial loss 13,517 12,680 11,834
-------------- ------------- --------------
Net periodic pension expense $ 24,800 $ 28,633 $ 32,385
============== ============= ==============
The discount rate used in determining the actuarial present value of the
projected benefit obligation was 7.50% at February 28, 2001 and February
29, 2000. The rate of return on plan assets was assumed to be 7.50% at
February 28, 2001 and February 29, 2000. No assumed increase in
compensation levels was used since future benefit accruals have ceased (as
discussed above). The unrecognized transition liability and unrecognized
net loss are being amortized over 30.4 and 18.2 years, respectively.
In fiscal 2001 and 2000, as required by Statement of Financial Accounting
Standards No. 87, the Company recorded a pension liability ($13,118 and
$82,910, respectively, included in "Accrued pension expense") to reflect
the excess of accumulated benefits over the fair value of pension plan
assets. Since the required additional pension liability is in excess of
the related unrecognized prior service cost (unrecognized transition
liability), an amount equal to the unrecognized prior service cost has
been recognized as an intangible asset ($135,693 and $143,484 included
in "Other assets" as of February 28, 2001 and February 29, 2000,
respectively). The remaining liability required to be recognized is
reported as a separate component of stockholders' equity.
25
The Company has a defined contribution retirement and savings plan (the
"401(k) Plan") designed to qualify under Section 401(k) of the Internal
Revenue Code (the "Code"). Eligible employees include those who are at
least twenty-one years old and who have worked at least 1,000 hours during
any one year. The Company may make matching contributions in amounts that
the Company determines at its discretion at the beginning of each year. In
addition, the Company may make further discretionary contributions.
Participating employees are immediately vested in amounts attributable to
their own salary or wage reduction elections, and are vested in Company
matching and discretionary contributions under a vesting schedule that
provides for ratable vesting over the second through sixth years of
service. The assets of the 40l(k) Plan are invested in stock, bond and
money market mutual funds. For the years ended February 28, 2001, February
29, 2000 and February 28, 1999, the Company made contributions totaling
$34,638, $32,447 and $27,387, respectively, to the 401(k) Plan.
(10) STOCK OPTIONS
The Company maintained a stock option plan for employees, officers,
directors, consultants and advisors of the Company covering 550,000 shares
of common stock (the "1992 Plan"). Options granted under the 1992 Plan are
exercisable for a period of either five or ten years at an exercise price
at least equal to 100 percent of the fair market value of the Company's
common stock at the date of grant. Options become exercisable under
various cumulative increments over the next nine years. The Board of
Directors has the discretion as to the persons to be granted options as
well as the number of shares and terms of the option agreements. The
expiration date of the plan is July 26, 2002. On February 13, 2001, the
Board of Directors approved and adopted, subject to shareholder approval,
a new stock incentive plan for a maximum of 1,500,000 shares of common
stock (the " 2001 Plan"). In December 2000, 175,000 incentive stock
options were granted to Andrew H. Meyers under the 1992 Plan and
80,000 incentive options were granted to Steven Goldstein under the
1992 Plan.
The Company has also granted non-incentive stock options. These options
are generally exercisable for a period of five or ten years and are issued
at a price equal to or lower than the fair market value of the Company's
common stock at the date of grant. On February 13, 2001, the Company
granted 30,000 non-incentive stock options at an exercise price of 1.525
per share to each of the Company's four outside directors under the 2001
Plan subject to shareholder approval of this plan and 100,000 options to
a consulting firm, the principal shareholder, which is owned by the sole
manager and voting member of Langer Partners LLC (see Note 2). At February
28, 2001, 240,000 non-incentive and 277,000 incentive stock options were
outstanding.
Options granted under both the 1992 Plan and the 2001 Plan exclude the
1,400,000 Options granted pursuant to the Tender Offer Agreement in
connection with the change in control (see Note 2).
26
The following is a summary of activity related to the Company's incentive and
non-incentive stock options:
EXERCISE WEIGHTED AVERAGE
NUMBER OF PRICE RANGE EXERCISE PRICE
SHARES PER SHARE PER SHARE
----------- ------------- -----------
Outstanding at February 28, 1998 251,250 $ .56 - $2.19 $1.35
Granted 175,000 1.13 1.13
Exercised (1,000) .78 .78
Cancelled (50,000) .75 .75
----------- ------------- -----------
Outstanding at February 28, 1999 375,250 .56 - 2.19 1.36
Granted 105,000 1.50-2.00 1.66
Exercised (42,000) .78-.88 .84
Cancelled (67,250) .56-2.19 1.64
----------------- --------------- --------
Outstanding at February 29, 2000 371,000 1.13 - 2.19 1.36
Granted 480,000 1.525- 1.69 1.53
Exercised (86,200) 1.13-2.00 1.36
Cancelled (247,800) 1.13 - 2.00 1.35
---------- ------------- ---------
Outstanding at February 28, 2001 517,000 $1.50 - $2.19 $ 1.54
========== =============== ========
At February 28, 2001, 246,000 options were exercisable, 271,000 options
were unexercisable and no options were available for issuance under the
1992 Plan. Upon shareholder approval of the 2001 Plan, 1,200,000
additional options will be available for grant. The options outstanding at
February 28, 2001 had remaining lives of between less than one year and
more than nine years, with a weighted average life of 7.52 years.
At February 28, 2001, there were 386,300 shares of common stock reserved
for issuance under the 1992 Plan.
ADDITIONAL STOCK PLAN INFORMATION
The Company continues to account for its stock-based awards using the
intrinsic value method in accordance with APB 25, "Accounting for Stock
Issued to Employees", and its related interpretations. Accordingly, no
compensation expense has been recognized in the financial statements for
employee stock arrangements.
SFAS No. 123, "Accounting for Stock-Based Compensation", requires the
disclosure of pro forma net income and net income per share had the
Company adopted the fair value method as of the beginning of fiscal 1997.
Under SFAS No. 123, the fair value of stock-based awards to employees is
calculated through the use of option pricing models, even though such
models were developed to estimate the fair value of freely tradeable,
fully transferable options without vesting restrictions, which
significantly differ from the Company's stock option awards. These models
also require subjective assumptions, including future stock price
volatility and expected time to exercise, which greatly affect the
calculated values. The Company's calculations were made using the
Black-Scholes option pricing model with the following weighted average
assumptions: expected life, 60 months following vesting; stock volatility
of 64.1 %, 38.1% and 39.08%, and risk free interest rates of 6.73 %, 5.9%
and 5.4% in fiscal 2001, 2000 and 1999, respectively, and no dividends
during the expected term. The Company's calculations are on a multiple
option valuation approach and forfeitures are recognized as they occur. If
the computed fair values of the award had been amortized to expense over
the vesting period of the awards, the pro forma net income and net income
per share for the years ended February 28, 2001, February 29, 2000 and
February 28, 1999 would have been net (loss) income of $(1,833,932), or
$(.71) per share, $(346,973) or $(.13) per share, and $170,020, or $.07
per share, respectively, on both a primary and fully diluted basis.
(11) EXPORT SALES AND OTHER INCOME
The Company had export sales from its United States operations of
approximately 25, 22 and 15 percent of net sales for each of the years
ended February 28, 2001, February 29, 2000 and February 28, 1999,
respectively.
Included in Other Income for the year ended February 28, 1999 is $150,000
related to the settlement of an insurance claim.
(12) SEGMENT INFORMATION
The Company operates in two segments (North America and United Kingdom)
principally in the design, development, manufacture and sale of foot and
gait-related products. Intersegment net sales are recorded at cost.
Segment
27
information for the years ended February 28, 2001, February 29, 2000
and February 28, 1999 are summarized as follows:
2001 NORTH AMERICA UNITED KINGDOM CONSOLIDATED TOTAL
------------------------------------------ ----------------- --------------- -------------------
Net sales from external customers $10,036,238 $1,605,914 $11,642,152
Intersegment net sales 248,390 - 248,390
Gross margins 3,121,133 658,021 3,779,154
Operating (loss) profit (1,587,547) 83,980 (1,503,567)
Depreciation and amortization 252,520 49,382 301,902
Total assets 3,855,618 698,601 4,554,219
Capital expenditures 38,465 10,916 49,381
------------------------------------------ ----------------- --------------- -------------------
2000
------------------------------------------ ----------------- --------------- -------------------
Net sales from external customers $9,598,346 $1,546,708 $11,145,054
Intersegment net sales 237,439 - 237,439
Gross margins 3,353,581 605,027 3,958,608
Operating (loss) profit (451,267) 95,207 (356,060)
Depreciation and amortization 267,994 33,475 301,469
Total assets 4,027,369 710,822 4,738,191
Capital expenditures 395,075 181,949 577,024
------------------------------------------ ----------------- --------------- -------------------
1999
------------------------------------------ ----------------- --------------- -------------------
Net sales from external customers $8,948,500 $1,358,814 $10,307,114
Intersegment net sales 176,277 - 176,277
Gross margins 3,207,393 542,521 3,749,914
Operating profit (68,615) 173,723 105,108
Depreciation and amortization 196,509 17,027 213,536
Total assets 4,633,039 491,541 5,124,580
Capital expenditures 100,351 6,795 107,146
------------------------------------------ ----------------- --------------- -------------------
(13) CREDIT FACILITIES
Upon closing of the Tender and the resultant change in control of
the Company, the Company's existing revolving credit facility with a bank was
terminated. In February 2001, the Company's President and Chief Executive
Officer loaned $500,000 to the Company evidenced by a promissory note,
bearing interest at prime plus 1% (9.5 % at February 28, 2001), which is due
August 31,2001,subject to prepayment under certain conditions including
exercising of the Options (see Note 2). Upon exercise of the Options on May
11, 2001, the principal amount of the loan, together with accrued interest in
the amount of $11,112 was exchanged by the CEO as partial consideration for
the payment of the shares of stock issued upon exercise of his portion of
the Options.
At February 28, 2001, $81,458 was outstanding on an $115,000
installment note to finance the acquisition of certain machinery and equipment
in the prior year. As a result of the Tender, this note became due and payable
and accordingly, has been classified as current. This note was repaid in March
2001. The loan bore interest at 9.5% per annum and required 48 monthly payments
of $2,396.
(14) RECONCILIATION OF BASIC AND DILUTED EARNINGS PER SHARE
Basic earnings per common share ("EPS") are computed based on the weighted
average number of common shares outstanding during each period. Diluted
earnings per common share are computed based on the weighted average
number of common shares, after giving effect to dilutive common stock
equivalents outstanding during each period. The following table provides a
reconciliation between basic and diluted earnings per share:
FOR THE YEAR ENDED
FEBRUARY 28, 2001 FEBRUARY 29, 2000 FEBRUARY 28, 1999
------------------- ------------------- ------------------
PER PER PER
INCOME SHARES SHARE INCOME SHARES SHARE INCOME SHARES SHARE
BASIC EPS
---------
(Loss) income available to
common stockholders $(1,506,387) 2,582,615 $ (.58) $(335,274) 2,571,004 $(.13) $ 304,490 2,584,336 $ .12
28
EFFECT OF DILUTIVE
SECURITIES -- -- -- -- -- -- 22,949 -- --
Stock options ------------ --------- -------- ---------- --------- ------ --------- --------- -----
DILUTED EPS
(Loss)income available to
common stockholders plus
exercise of stock options $(1,506,387) 2,582,615 $ (.58) $(335,274) 2,571,004 $(.13) $304,490 2,607,285 $.12
============ ========= ======= ========= ========= ====== ======== ========= ====
29
THE LANGER BIOMECHANICS GROUP, INC.
AND SUBSIDIARIES
VALUATION AND QUALIFYING ACCOUNTS
SCHEDULE II
FOR THE YEARS ENDED FEBRUARY 28, 2001, FEBRUARY 29, 2000 AND FEBRUARY 28, 1999
ALLOWANCE
SALES FOR DOUBTFUL
RETURNS AND ACCOUNTS WARRANTY INVENTORY
ALLOWANCES RECEIVABLE RESERVE RESERVE
-------------- ------------- ------------- -------------
At February 28, 1998 $ 32,058 $ 23,349 $ 33,797 $ 59,011
Additions 14,000 59,788 13,000 27,000
Deletions - 46,982 18,484
-------------- ------------- ------------- -------------
At February 28, 1999 46,058 36,155 46,797 67,527
Additions - 31,167 - -
Deletions - 4,669 - 11,797
-------------- ------------- ------------- -------------
At February 29, 2000 46,058 62,653 46,797 55,730
Additions - 19,000 21 137,593
Deletions 17,259 23,833 - -
---------------- ------------- ------------- -------------
At February 28, 2001 $ 28,799 $ 57,820 $ 46,818 $ 193,323
============== ============= ============= =============
30
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE
Not applicable.
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
OFFICERS AND DIRECTORS
The executive officers and directors of the Company are as follows:
NAME AGE OFFICE
-------------------- --- ----------------------------------------------------
Burtt R. Ehrlich 61 Chairman of the Board
Andrew H. Meyers 44 President and Chief Executive Officer; Director
Jonathan R. Foster 43 Director
Greg Nelson 51 Director
Arthur Goldstein 69 Director
Steven Goldstein 35 Vice President
Thomas G. Archbold 41 Vice President - Finance and Chief Financial Officer
Burtt R. Ehrlich has been Non-Executive Chairman of the Board; Director of
the Company since February 13, 2001. He has served as a director of Armor
Holdings since January 1996. Mr. Ehrlich served as Chairman and Chief Operating
Officer of Ehrlich Bober Financial Corp. (the predecessor of Benson Eyecare
Corporation) from December 1986 until October 1992 and as a director of Benson
Eyecare Corporation from October 1992 until November 1995.
Andrew H. Meyers has been the President and Chief Executive Officer;
Director of the Company since February 13, 2001 and an employee from December
28, 2000 as an advisor to the Board of Directors in association with the
making of the Tender. He has been an executive in the orthotics industry
since 1979. From March, 1992 to December, 1996, Mr. Meyers was the President
and Chief Executive Officer of Advanced Orthopedic Technologies, Inc.
("AOTI"), a publicly held company. In December 1996, AOTI was acquired by
NovaCare Orthotics and Prosthetics, Inc.; Mr. Meyers supervised its
integration into NovaCare, and from December 1996 until July 1999 Mr. Meyers
served NovaCare in various executive positions, most recently being Executive
Vice President of Sales and Marketing. When NovaCare sold its orthotics and
prosthetics business to Hanger Orthopedic Group in July 1999, Mr. Meyers
became Hanger's Executive Vice President of Marketing, Public Relations and
Strategic Planning. In September 2000, Mr. Meyers resigned from Hanger to
pursue his strategy of acquiring a company in the musculoskeletal industry.
Jonathan R. Foster has been a Director of the Company since February 13,
2001. He joined Howard Capital Management in 1994 as President. In addition to
overseeing the firm's operations and strategic development, he manages the
portfolios of numerous individuals and families. Mr. Foster also is responsible
for managing Howard Capital Management's West Coast operations. With two decades
of experience in finance and wealth management, Mr. Foster previously was
managing general partner of Jonathan Foster & Co., LP, a private investment
boutique he founded in 1987. Prior to that, he was an associate director of
Bear, Stearns & Co., LP. Mr. Foster's earlier finance experience includes
positions at Edelman Group and Oppenheimer & Company. Mr. Foster is a director
of Troma Entertainment, Inc. He received his BA in Political Science from the
University of Pennsylvania.
31
Arthur Goldstein has been a Director of the Company since February 13,
2001. He is President of AGA Associates, investment advisors founded in 1986.
Prior to that, Mr. Goldstein was a financial advisor at several brokerage
firms. His management experience includes President of Butler Industries,
Div.of Safeguard Ind. (SFE, NYSE), and Chairman of Rudor Industries, a
multi-division service organization. He was also Chairman of Gerber
Industries, designers of department store interiors from 1980 to 1983. Mr.
Goldstein received his BS in Management from Rensselaer Polytechnic
Institute. He was also a trustee of New York Medical College and a member of
the Young Presidents Organization.
Greg Nelson has been a Director of the Company since February 13, 2001. He
was a co-founder of DonJoy Orthopedics, a sports medicine, knee brace company,
which today is called dj Orthopedics. As President, he helped grow the company
from a start-up operation to annual sales over $70 million. DonJoy was sold to
Smith+Nephew, a British-based healthcare company in 1987. Mr. Nelson is
currently Chairman of BREG, Inc. which he helped co-found in 1990. BREG is a
diverse orthopedic company with product lines including cold therapy, pain care
products, knee bracing and soft goods.
Steven Goldstein has been a Vice President and Secretary of the Company since
February 13, 2001 and an employee of the Company from December 28, 2000 in
connection with the Tender. Mr. Goldstein has been Vice President of Clinical
Sales and Marketing for Hanger Orthopedic Group (NYSE:HGR) a national provider
of orthotic and prosthetic services since July 1999. In June 1999, Hanger
acquired NovaCare's Orthotics and Prosthetics Division (NYSE:NOV), where he
served as Director, Clinical Sales and Marketing. In 1996 NovaCare acquired
Advanced Orthopedic Technologies (NASDAQ:AOTI) where he served as Regional
Director of Patient Care Facilities. In 1996 Advanced Orthopedic Technologies
Acquired Med-Tech Orthotics and Prosthetics a private organization, where he
served as President and Chief Executive Officer.
Mr. Archbold has been Vice President of Finance and Chief Financial Officer
since June 1999. From 1996 to 1999, he was Corporate Controller of United
Capital Corporation, a publicly traded company with interests in real estate and
manufacturing. From 1994 to 1996, he was Director of Finance of AIL Systems,
Inc., a manufacturer of electronic equipment. Prior to that, Mr. Archbold spent
nine years with Ernst & Young LLP, including four years as an audit senior
manager, and he is a CPA. He received a Bachelor of Sciences in Accounting from
C.W. Post College.
All directors are normally elected at the annual meeting of shareholders to
hold office until the next annual meeting and until their successors are duly
elected and qualified. The Company's By-Laws provide that the annual meeting of
shareholders be held each year at a time and place to be designated by the Board
of Directors. Directors may be removed at any time for cause by the Board of
Directors and with or without cause by a majority of the votes cast at a meeting
of shareholders entitled to vote for the election of directors.
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
The Company is not aware of any late filings of, or failures to file,
during the fiscal year ended February 28, 2001, the reports required by Section
16(a) of the Securities Exchange Act of 1934.
LIMITATION ON LIABILITY OF DIRECTORS
As permitted by New York law, the Company's Certificate of Incorporation
contains an article providing for the elimination of the personal liability of
the directors of the Company to the fullest extent permitted by the provisions
of paragraph (b) of Section 402 of the New York Business Corporation Law.
Accordingly, a director's personal liability would be eliminated for any breach
of a director's duty, unless, among other things, the director's actions or
omissions were in bad faith, involved intentional misconduct or a knowing
violation of the law, or personal gain in fact of a financial profit to which
the director was not lawfully entitled. This article is intended to afford
directors additional protection, and limit their potential liability, from suits
alleging a breach of the duty of care by a director. The Company believes this
article enhances the Company's ability to attract and retain qualified persons
to serve as directors. As a result of the inclusion of such a provision,
shareholders may be unable to recover monetary damages against directors for
actions taken by them which constitute negligence or gross negligence or which
are in violation of their fiduciary duties, although it may be possible to
obtain injunctive or other equitable relief with respect to such actions. If
equitable remedies are found not to be available to shareholders for any
particular case, shareholders may not have any effective remedy against the
challenged conduct.
32
ITEM 11. EXECUTIVE COMPENSATION
SUMMARY COMPENSATION TABLE
The following table shows the cash compensation received by the four
executive officers either whose compensation (salary and bonus) exceeded
$100,000 during the fiscal year ended February 28, 2001 or was Chief Executive
Officer of the Company during such year (the "named executive officers"):
LONG-TERM
ANNUAL COMPENSATION COMPENSATION
-------------------------- ----------------
NAME AND FISCAL SALARY BONUS OTHER OPTIONS
PRINCIPAL POSITION YEAR $ $ $ (NO. OF SHARES)
-------------------------- ------ ----------- ----------- ---------- ---------------
Andrew H. Meyers 2001 6,731(1) (5) 175, 000
President and Chief
Executive Officer
Daniel J. Gorney 2001 160,000(2) - 30,625
Former President and 2000 158,830 - (5) 25,000
Chief Executive Officer 1999 34,663 - (5) 75,000
Thomas G. Archbold 2001 135,923 9,500 (5) -
Vice President and Chief 2000 89,551(3) - (5) 25,000
Financial Officer
Ronald Spinelli 2001 128,539 5,000 (5) -
Vice President-Operations 2000 49,061(4) - (5) 20,000
(1) Mr. Meyers' employment commenced on December 28, 2000 in an unpaid
capacity as an advisor to the Board of Directors and his official duties
as President and Chief Executive Officer commenced on February 13, 2001.
(2) Mr. Gorney's employment commenced on November 30, 1998 and he resigned as
chief executive officer effective February 13, 2001. Other compensation in
fiscal 2001 consists of the redemption of outstanding Options in
connection with the change in control.
(3) Mr. Archbold's employment commenced June 14, 1999.
(4) Mr. Spinelli's employment commenced October 1, 1999.
(5) Less than 10% of the total annual salary and bonus.
33
OPTION GRANTS IN LAST FISCAL YEAR
OPTION GRANTS DURING THE FISCAL YEAR ENDED FEBRUARY 28, 2001 TO THE FOUR NAMED
EXECUTIVE OFFICERS WERE AS FOLLOWS:
POTENTIAL REALIZABLE VALUE
AT ASSUMED ANNUAL RATES OF
STOCK PRICE
APPRECIATION FOR OPTION
TERM (1)
INDIVIDUAL GRANTS
- -------------------------------------------------------------------------------------------------------------------------
NUMBER OF PERCENT OF TOTAL
SECURITIES OPTIONS GRANTED EXERCISE
UNDERLYING TO EMPLOYEES IN OR BASE
OPTIONS GRANTED FISCAL YEAR PRICE EXPIRATION
NAME (#) ($/SH) DATE 5% ($) 10% ($)
- -------------------------------------------------------------------------------------------------------------------------
Andrew H. Meyers 175,000 36.4 $1.525 2/13/11 $731,500 $1,321,250
Daniel J. Gorney - - - - - -
Thomas G. Archbold - - - - - -
Ronald Spinelli - -
(1) The potential realizable value portion of the foregoing table
illustrates value that might be received upon exercise of the
options immediately prior to the expiration of their term, assuming
the specified compounded rates of appreciation on the Company's
common stock over the term of the options. These numbers do not take
into account provisions of certain options providing for termination
of the option following termination of employment.
FISCAL YEAR-END OPTION VALUES
The table below sets forth information regarding unexercised options held
by the Company's named executive officers as of February 28, 2001. During
fiscal 2001, 9,000 options and 7,200 options at $2.00 were exercised by Messrs.
Archbold and Spinelli, respectively.
NUMBER OF SECURITIES UNDERLYING VALUE OF UNEXERCISED
UNEXERCISED OPTIONS AT IN-THE-MONEY OPTIONS
FISCAL YEAR END AT FISCAL YEAR END
EXERCISABLE/UNEXERCISABLE EXERCISABLE/UNEXERCISABLE
NAME (#) $ (1)
- -------------------------- ------------------------------- -------------------------
Andrew H. Meyers - / 175,000 - / 346,625
Daniel J. Gorney - / - - / -
Thomas G. Archbold - / 16,000 - / 32,000
Ronald Spinelli - / - - / -
(1) The closing bid price of the Company's common stock as reported by
NASDAQ on February 28, 2001 was $3.50. Value is calculated on the
difference between the option exercise price of in- the-money
options and $3.50 multiplied by the number of shares of common
stock underlying the option.
LONG-TERM INCENTIVE PLAN-AWARDS IN LAST FISCAL YEAR
None.
COMPENSATION OF DIRECTORS
Members of the Board of Directors prior to the change in control, who were
not executive officers of the Company, were compensated by means of the issuance
of shares of Common Stock. During Fiscal 2001 the outside Directors on the Board
of Directors prior to the change in control ( Mr. Ardia, Mr.Granat and
34
Mr.Altholz) were issued 7,000 shares of common stock of the Company. Directors
are reimbursed for their out-of-pocket expenses in connection with the
attendance of Board of Directors meetings.
Members elected to the Board of Directors subsequent to the change in
control, who are not executive officers of the Company, are expected to be
principally compensated through the issuance of stock and stock options. Mr.
Ehrlich will receive annual compensation of $10,000 for services as
Non-executive Chairman of the Board. On February 13, 2001 certain of the
outside directors purchased restricted shares of the Company at a price of
$1.525. Messrs. Ehrlich, Goldstein and Foster purchased 65,574, 32,787 and
49,180 shares, respectively. Additionally, each of the four outside Directors
who are not executive officers of the Company were issued non-qualified
options to purchase 30,000 shares of common stock of the Company at a price
of $1.525 under the 2001 Plan subject to shareholder approval of the 2001
Plan. Directors are reimbursed for their out-of-pocket expenses in connection
with the attendance of Board of Directors meetings.
EMPLOYMENT AGREEMENTS
As of December 28, 2000, the company entered into an Employment Agreement
with Andrew H. Meyers which provides that he will serve as President and Chief
Executive Officer for a three year term that will expire December 31, 2003,
subject to early termination as described below. The agreement provides for a
base salary of $175,000. Mr. Meyers also received options under 1992 Stock
Option Plan effective as of December 28, 2000 to purchase 175,000 shares of
common stock at an exercise price per share equal to $1.525. These options vest
over a period of three years from the date of grant. Pursuant to his employment
agreement, Mr. Meyers may be entitled, at the discretion of the Compensation
Committee of the board, to participate in the other option plans and other bonus
plans the Company has adopted based on his performance and the Company's overall
performance. The Company is required to purchase $1 million of life insurance
payable to a beneficiary designated by Mr. Meyers. The Company also has the
right to purchase $5 million of key-man life insurance on Mr. Meyer's life. A
"change in control" of the Company will allow Mr. Meyers to terminate his
employment agreement and to receive payment of $300,000 over a period of one
year in addition to any accrued but unpaid obligations of the Company, as well
as the vesting of all 175,000 options granted to him under the employment
agreement. Mr. Meyers will also be entitled to such payment and the acceleration
of such vesting on the 175,000 options upon the termination of his employment
agreement by the Company without cause. Such 175,000 options will terminate in
the event that Mr. Meyer's employment agreement is terminated by the Company for
cause. Mr. Meyers has also agreed to certain confidentiality and non-competition
provisions and subject to certain exceptions and limitations, to not sell,
transfer or dispose of the shares of common stock of options for the purchase of
common stock of the Company owned by him until December 31, 2003.
As of December 28, 2000, the Company entered into an Employment Agreement
with Steven Goldstein which provides that he will serve as Vice President for a
three year term expiring December 31, 2003, at a base salary of $140,000 for the
first year, $155,000 for the second year and $165,000 for the third year. In
addition to his base salary, Mr.Goldstein received options under the 1992 Stock
Option Plan effective as of December 28, 2000 to purchase 80,000 shares of
Common Stock at an exercise price per share equal to $1.525. These options vest
over a period of three years from the date of the grant. Pursuant to his
employment agreement, Mr.Goldstein will be entitled, at the discretion of the
Compensation Committee of the board, to participate in the incentive stock
option plan and other bonus plans the Company has adopted based on his
performance and the Company's overall performance. Additionally, the Agreement
provides for a $50,000 signing bonus, of which $30,000 was paid immediately and
$20,000 shall be paid on February 13, 2002, and for a guaranteed minimum bonus
of $10,000 per year for each of the three years of the contract, provided that
Mr.Goldstein has not voluntarily terminated this Agreement without "Good Reason"
or that the Company has not terminated the Agreement for cause. In the event of
termination of Mr. Goldstein's employment for Good Reason or disability, all
unvested remaining options will vest immediately. Such 80,000 options will
terminate in the event that Mr. Goldstein's employment agreement is terminated
by the Company for cause. Mr. Goldstein has agreed to certain confidentiality
and non-
35
competition provisions, and to not sell, transfer or dispose of the
80,000 options (and underlying shares) granted to him under his employment
agreement until December 31, 2003.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth, as of May 15, 2001, the shares of common
stock owned beneficially and of record (unless otherwise indicated) by each
person owning more than five percent (5%) of the outstanding shares, each
director of the Company, each named executive officer of the Company and all
directors and officers of the Company as a group.
NUMBER OF
NAME (AND ADDRESS OF 5% HOLDERS) SHARES OWNED PERCENT
-------------------------------- ------------ -------
Langer Partners LLC 1,591,856(1) 36.2 %
Two Soundview Drive
Greenwich, CT 06830
Andrew H. Meyers 902,580(4) 20.5 %
31 The Birches
Roslyn Estates, New York 11576
Gregory R. Nelson 227,721(3) 5.2 %
3664 Maria Lane
Carlsbad, CA 92008
NUMBER OF
NAME SHARES OWNED PERCENT
---------------------------------- ------------ ---------
Burtt R. Ehrlich 190,574(3)(6) 4.3 %
Arthur Goldstein 62,787(3) 1.4 %
Jonathan R. Foster 128,360(3) 2.9 %
Steven Goldstein 19,672(5) .5 %
---
Thomas G. Archbold 4,000(2) .1 %
---
All Directors and Officers
as a Group (7 persons) 1,320,694(2) 34.9%
(1) Includes 100,000 options granted to Kanders & Co. exercisable
immediately. Warren B. Kanders is the sole voting member and sole
shareholder of Langer Partners LLC and the sole shareholder of
Kanders & Co. Inc.
(2) Includes 4,000 shares issuable under outstanding stock options
exercisable within sixty days.
(3) Includes 30,000 options granted to each of the four outside directors
which were immediately exercisable.
(4) Excludes options to purchase 175,000 shares pursuant to 1992 Plan.
(5) Excludes options to purchase 80,000 hares pursuant to 1992 Plan.
(6) Includes 42,500 shares held in trust by Mrs. Burtt Ehrlich as trustee
for the benefit of David Ehrlich and 31,500 shares held in trust by
Mrs. Burtt Ehrlich as trustee for the benefit of Julie Ehrlich, for
which Mr. Ehrlich disclaims beneficial ownership.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
36
OPTION GRANT AND REGISTRATION RIGHTS AGREEMENT. In connection with the grant of
the Options to Andrew H. Meyers, Greg Nelson and Langer Partners LLC to purchase
1,400,000 shares of Common Stock, pursuant to the Tender Offer Agreement, the
Company entered into a Registration Rights Agreement, pursuant to which it will
use its best efforts to register the shares underlying such option and any other
shares held by the holders of the shares underlying such option under the
Securities Act of 1933, as amended, during the three year period commencing on
the date of such Registration Rights Agreement at the request of holders of at
least 50% of such shares. Pursuant to such Registration Rights Agreement, the
Company agreed to register such shares if the Company, for itself or for any of
its security holders, shall at anytime register shares under the Securities Act,
except in the case of registrations of shares pursuant to the Company's stock
option plans. The Company will also pay all expenses incurred in connection with
any such registration. Andrew H. Meyers and Greg Nelson are subject to
lock-up agreements with the Company and Kanders & Company Inc. restricting
the sale of shares under certain conditions for a period of three years.
ARDIA CONSULTING AGREEMENTS. On November 29, 2000, the Company agreed to pay
Stephen V. Ardia, the then Chairman of the Board, the sum of $25,000 for his
services rendered in connection with the negotiation of the transactions
contemplated by the Tender. In January 2001, Langer paid $40,000 to Mr. Ardia,
which amounts had previously not been paid but were due and owing to Mr. Ardia
for his services to the Company from November 1998 to November 2000.
OFFICER BONUS AND SEVERANCE AGREEMENTS. As an incentive to the Company's
executive officers prior to the change in control who were not Directors (Daniel
J. Gorney, President and CEO; Thomas G. Archbold, Chief Financial Officer; and
Ronald Spinelli, Vice President of Operations) to remain in the employ of the
Company through the closing of the Tender and to assist in the transition period
following the Closing, the Company agreed to pay stay bonuses to such executives
if certain performance targets are met at the month end preceding the Closing of
the Tender. Such bonuses were up to $20,000 for Mr. Gorney, $20,000 for Mr.
Archbold and $25,000 for Mr. Spinelli, with minimum guaranteed bonuses to
Messrs. Archbold and Spinelli of $5,000 each. To receive such bonus, such
individuals were required to remain in the employ of the Company for 90 days
following the Closing of the Tender. The only bonuses due and payable are the
minimum bonuses which have not yet been paid. Langer will provide three months
base salary as a severance payment to Messrs. Archbold and Spinelli if they are
terminated without cause within six months of the Closing of the Tender. Mr.
Spinelli's employment was terminated and he was paid three months severance in
March 2001. The Company committed to continue to employ Mr. Gorney, and Mr.
Gorney committed to remain employed with the Company, for three months after the
Closing of the Offer; thereafter Mr. Gorney was entitled to receive three months
base salary as a severance payment.
CONSULTING AGREEMENT WITH KANDERS & COMPANY, INC. Upon consummation of the
Tender, the Company entered into, a Consulting Agreement (the "Consulting
Agreement") with Kanders & Company, Inc., the sole shareholder of which is
Warren B. Kanders, the sole manager and voting member of Langer Partners LLC a
principal shareholder of the Company. The Consulting Agreement provides that
during its term Kanders & Company, Inc. will act as a non-exclusive consultant
to the Company and will provide the Company with general investment banking and
financial advisory services, including assistance in the development of a
corporate financing and acquisition strategy. The Consulting Agreement provides
for an initial term of three years. Pursuant to the Agreement, Kanders &
Company, Inc. is to receive an annual fee of $100,000, and was granted options,
exercisable immediately ("Consultant's Options") to purchase 100,000 shares of
the Company at a price of $1.525 per share and reimbursement for out-of-pocket
expenses. The Consulting Agreement indemnifies Kanders & Company, Inc., against
any claims brought against the Company or Kanders & Company, Inc. arising out of
activities undertaken by Kanders & Company, Inc. at the request of the Company.
In addition, the Consulting Agreement provides for separate engagement letters
in connection with specific transactions for which Kanders & Company, Inc. will
provide additional services for the Company. Kanders & Company, Inc. agreed
that, during the term of the Consulting Agreement and for a period of one year
thereafter, it will not solicit or engage in any business competitive with the
business of the Company or, subject to certain limitations, invest in or give
financial support to any business competitive with that of the Company. In
connection with the issuance of the Consultant's Options, the Company granted to
37
Kanders & Company, Inc. certain compulsory, demand and "piggy-back" registration
rights with respect to the securities issuable upon exercise of the Consultant's
Options. The Consultant's Registration Rights Agreement contains certain
covenants and agreements customary for such agreements, including an agreement
by the Company to indemnify Kanders & Company, Inc. from certain liabilities
under the Securities Act in connection with the registration of the securities
underlying the Consultant's Options.
ANDREW H. MEYERS LOAN TO COMPANY. In February 2001, the Company's President
and Chief Executive Officer loaned $500,000 to the Company evidenced by a
promissory note due August 31, 2001, bearing interest at prime plus 1% (9.5%
at February 28, 2001) which the Company believes is comparable to the
interest rate it would have to pay for loans from third parties, subject to
prepayment under certain conditions including exercise of the Options (see
Note 2). The Options were exercised on May 11, 2001 and Mr. Meyers converted
the principal amount of the loan together with accrued interest in the amount
of $11,112 as partial consideration for the payment of the shares of stock
issued upon exercise of his portion of the Options.
38
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULE, AND REPORTS ON FORM 8-K
(a) 1. FINANCIAL STATEMENTS
The following consolidated financial statements are filed as part of this
Form l0-K:
Independent Auditors' Report
Consolidated Financial Statements:
Consolidated Balance Sheets as of February 28, 2001 and
February 29, 2000
Consolidated Statements of Operations for the years ended
February 28, 2001, February 29, 2000 and February 28, 1999
Consolidated Statements of Stockholders' Equity for the years ended
February 28, 2001, February 29, 2000 and February 28, 1999
Consolidated Statements of Cash Flows for the years ended
February 28, 2001, February 29, 2000 and February 28, 1999
Notes to Consolidated Financial Statements
2. FINANCIAL STATEMENT SCHEDULES
The following Financial Statement Schedule is filed as part of this
Form 10-K:
Schedule II - Valuation and Qualifying Accounts for the years ended
February 28, 2001, February 29, 2000 and
February 28, 1999
All other schedules have been omitted because they are not applicable,
not required or the information is disclosed in the consolidated
financial statements, including the notes thereto.
3. EXHIBITS
NUMBER DOCUMENT
- ------ --------
2.1 Tender Offer Agreement, dated as of December 28, 2000, between
OrthoStrategies, OrthoStrategies Acquisition Corp., and Langer
(filed as Exhibit (d)(1)(A) to Schedule TO, Tender Offer Statement,
filed with the Securities and Exchange Commission on January 10,
2001 ("Schedule TO") and incorporated herein by reference).
3.1 Certificate of Incorporation of the Company incorporated by
reference to the Company's Registration Statement of Form S-1 (No.
2-87183), which became effective with the Securities and Exchange
Commission on January 17, 1984 ("S-1").
3.2 Bylaws of the Company, as amended through July 2, 1987 incorporated
by reference to Post-effective Amendment No. 1 to the Company's
Registration Statement on Form S-8.
4.1 Specimen of Common Stock Certificate incorporated by reference to
the Company's Registration Statement of Form S-1 (No. 2-87183),
which became effective with the Securities and Exchange Commission
on January 17, 1984.
10.1* Option Agreement with Andrew H. Meyers, dated February 13, 2001.
10.2 Option Agreement with Langer Partners, LLC, dated February 13, 2001.
10.3* Option Agreement with Jonathan Foster, dated February 13, 2001.
10.4* Option Agreement with Greg Nelson, dated February 13, 2001.
10.5 Form of Registration Rights Agreement between the Company and Andrew
H. Meyers, Langer Partners, LLC, Jonathan Foster, and Greg Nelson,
dated February 13, 2001.
10.6* Employment Agreement between the Company and Andrew H. Meyers, dated
as of February 13, 2001.
10.7* Employment Agreement between the Company and Steven Goldstein, dated
as of February 13, 2001.
39
10.8* Option Agreement between the Company and Andrew H. Meyers, dated as
of December 28, 2000.
10.9* Option Agreement between the Company and Steven Goldstein, dated as
of December 28, 2000.
10.10* Consulting Agreement between the Company and Kanders & Company,
Inc., dated February 13, 2001 (the form of which was filed as
Exhibit (d)(1)(H) to the Schedule TO and is incorporated herein by
reference).
10.11* Option Agreement between the Company and Kanders & Company, Inc.,
dated February 13, 2001 (the form of which was filed as Exhibit
(d)(1)(G) to the Schedule TO and is incorporated herein by
reference).
10.12 Registration Rights Agreement between the Company and Kanders &
Company, Inc., dated February 13, 2001 (the form of which was filed
as Exhibit (d)(1)(I) to the Schedule TO and is incorporated herein
by reference).
10.13 Indemnification Agreement between the Company and Kanders & Company,
Inc., dated February 13, 2001 (the form of which was filed as
Exhibit (d)(1)(J) to the Schedule TO and is incorporated herein by
reference).
10.14 Letter Agreement among the Company, OrthoStrategies, OrthoStrategies
Acquisition Corp, Steven V. Ardia, Thomas I. Altholz, Justin
Wernick, and Kenneth Granat, dated December 28, 2000 (filed as
Exhibit (d)(1)(K) to the Schedule TO and incorporated herein by
reference).
10.15* Letter Agreement between the Company and Daniel Gorney, dated as of
December 28, 2000 (filed as Exhibit (d)(1)(O) to the Schedule TO and
incorporated herein by reference).
10.16* Letter Agreement between the Company and Thomas Archbold, dated as
of December 28, 2000 (filed as Exhibit (d)(1)(P) to the Schedule TO
and incorporated herein by reference).
10.17* Letter Agreement between the Company and Ronald J. Spinilli, dated
as of December 28, 2000 (filed as Exhibit (d)(1)(Q) to the Schedule
TO and incorporated herein by reference).
10.18* Stock Option Plan incorporated by reference to the Company's Form
10-K for the fiscal year ended February 28, 1993.
40
10.19 Langer Biomechanics Group Retirement Plan, restated as of July 20,
1979 and incorporated by reference to the S-1.
10.20 Agreement, dated March 26, 1992, and effective as of March 1, 1992,
relating to the Company's 401(k) Tax Deferred Savings Plan and
incorporated by reference to the Company's Form 10-K for the fiscal
year ended February 29, 1992.
10.21* Consulting Agreement between the Company and Stephen V. Ardia, dated
November 29, 2000.
10.22* Promissory Note of the Company in favor of Andrew H. Meyers, dated
February 13, 2001 (filed as Exhibit 99.1 to the Company's Form 8-K
Current Report, dated February 13, 2001, and incorporated herein by
reference).
10.23 Form of Indemnification Agreement for non-management directors of
the Company . 10.24 Copy of Lease related to the Company's Deer Park
facilities filed as Exhibit to the Company's Form 10-K for the
fiscal year ended February 29,2000.
10.25 Copy of Agreement, dated July 8, l986, between BioResearch Ithaca,
Inc. and the Company relating the licensing of the Pediatric Counter
Rotation System incorporated by reference to the Company's Form 10-K
for the year ended July 31,1986.
21.1 List of subsidiaries
23.1 Consent of accountants
* This exhibit represents a management contract or a compensatory plan
(b) REPORTS ON FORM 8-K:
The Company filed a report on Form 8-K on January 5, 2001 to
report the signing of the Tender Offer Agreement dated December 28, 2000
between the Company and OrthoStrategies Acquisition Corporation ("OSA")
pursuant to which OSA agreed to make a Tender Offer for up to 75% of the
common stock of the Company at $1.525 per share.
The Company filed a report on Form 8-K on February 28, 2001 to
report that pursuant to the Tender Offer Agreement dated December 28,
2000, Andrew H. Meyers, Greg Nelson and Langer Partners LLC acquired a
controlling interest in the Company when they purchased 1,362,509 validly
tendered shares of the Company at $1.525, or approximately 51% of the
then outstanding common stock of the Company.
41
SIGNATURES
Pursuant to the requirements of Section l3 or l5(d) of the Securities
Exchange Act of l934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
THE LANGER BIOMECHANICS GROUP, INC.
Date: May 22, 2001 By: /s/ Andrew H. Meyers
-----------------------------------
Andrew H. Meyers, President and
Chief Executive Officer
(Principal Executive Officer)
By: /s/Thomas G. Archbold
-----------------------------------
Thomas G. Archbold, Vice President
-Finance (Principal Financial and
Accounting Officer)
Pursuant to the requirements of the Securities Exchange Act of l934, this
report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.
Date: May 22, 2001 By: /s/ Burtt Ehrlich
-----------------------------------
Burtt Ehrlich, Director
Date: May 22, 2001 By: /s/ Arthur Goldstein
-----------------------------------
Arthur Goldstein, Director
Date: May 22, 2001 By: /s/ Greg Nelson
-----------------------------------
Greg Nelson, Director
Date: May 22, 2001 By: /s/ Jonathan Foster
-----------------------------------
Jonathan Foster, Director
42
Exhibit Index
3. EXHIBITS
EXHIBIT
NO. DESCRIPTION
2.1 Tender Offer Agreement, dated as of December 28, 2000, between
OrthoStrategies, OrthoStrategies Acquisition Corp., and Langer
(filed as Exhibit (d)(1)(A) to Schedule TO, Tender Offer
Statement, filed with the Securities and Exchange Commission on
January 10, 2001 ("Schedule TO") and incorporated herein by
reference).
3.1 Certificate of Incorporation of the Company (filed as Exhibit ___
to the Company's Registration Statement of Form S-1 (No. 2-87183),
which became effective with the Securities and Exchange Commission
on January 17, 1984 ("S-1"), and incorporated herein by
reference).
3.2 Bylaws of the Company, as amended through July 2, 1987 (filed as
Exhibit ___ to the Post-effective Amendment No. 1 to the Company's
Registration Statement on Form S-8 and incorporated herein by
reference).
4.1 Specimen of Common Stock Certificate (filed as Exhibit ___ to the
Company's Registration Statement of Form S-1 (No. 2-87183), which
became effective with the Securities and Exchange Commission on
January 17, 1984, and incorporated herein by reference).
10.1* Option Agreement with Andrew H. Meyers, dated February 13, 2001.
10.2 Option Agreement with Langer Partners, LLC, dated February 13,
2001.
10.3* Option Agreement with Jonathan Foster, dated February 13, 2001.
10.4* Option Agreement with Greg Nelson, dated February 13, 2001.
10.5 Form of Registration Rights Agreement between the Company and
Andrew H. Meyers, Langer Partners, LLC, Jonathan Foster, and Greg
Nelson, dated February 13, 2001.
10.6* Employment Agreement between the Company and Andrew H. Meyers,
dated as of February 13, 2001.
10.7* Employment Agreement between the Company and Steven Goldstein,
dated as of February 13, 2001.
10.8* Option Agreement between the Company and Andrew H. Meyers, dated
as of December 28, 2000.
10.9* Option Agreement between the Company and Steven Goldstein, dated
as of December 28, 2000.
10.10* Consulting Agreement between the Company and Kanders & Company,
Inc., dated February 13, 2001 (the form of which was filed as
Exhibit (d)(1)(H) to the Schedule TO and is incorporated herein by
reference).
10.11* Option Agreement between the Company and Kanders & Company, Inc.,
dated February 13, 2001 (the form of which was filed as Exhibit
(d)(1)(G) to the Schedule TO and is incorporated herein by
reference).
10.12 Registration Rights Agreement between the Company and Kanders &
Company, Inc., dated February 13, 2001 (the form of which was
filed as Exhibit (d)(1)(I) to the Schedule TO and is incorporated
herein by reference).
10.13 Indemnification Agreement between the Company and Kanders &
Company, Inc., dated February 13, 2001 (the form of which was
filed as Exhibit (d)(1)(J) to the Schedule TO and is incorporated
herein by reference).
10.14 Letter Agreement among the Company, OrthoStrategies,
OrthoStrategies Acquisition Corp, Steven V. Ardia, Thomas I.
Altholz, Justin Wernick, and Kenneth Granat, dated December 28,
2000 (filed as Exhibit (d)(1)(K) to the Schedule TO and
incorporated herein by reference).
10.15* Letter Agreement between the Company and Daniel Gorney, dated as
of December 28, 2000 (filed as Exhibit (d)(1)(O) to the Schedule
TO and incorporated herein by reference).
10.16* Letter Agreement between the Company and Thomas Archbold, dated as
of December 28, 2000 (filed as Exhibit (d)(1)(P) to the Schedule
TO and incorporated herein by reference).
10.17* Letter Agreement between the Company and Ronald J. Spinilli, dated
as of December 28, 2000 (filed as Exhibit (d)(1)(Q) to the
Schedule TO and incorporated herein by reference).
10.18* Stock Option Plan (filed as Exhibit ___ to the Company's Form 10-K
for the fiscal year ended February 28, 1993 and incorporated
herein by reference).
10.19 Langer Biomechanics Group Retirement Plan, restated as of July 20,
1979 (filed as Exhibit ___ to the S-1 and incorporated herein by
reference).
10.20 Agreement, dated March 26, 1992, and effective as of March 1,
1992, relating to the Company's 401(k) Tax Deferred Savings Plan
(filed as Exhibit ___ to the Company's Form 10-K for the fiscal
year ended February 29, 1992 and incorporated herein by
reference).
10.21* Consulting Agreement between the Company and Stephen V. Ardia,
dated November 29, 2000.
10.22* Promissory Note of the Company in favor of Andrew H. Meyers, dated
February 13, 2001 (filed as Exhibit 99.1 to the Company's Form 8-K
Current Report, dated February 13, 2001, and incorporated herein
by reference).
10.23 Form of Indemnification Agreement for non-management directors of
the Company.
21.1 List of subsidiaries
23.1 Consent of accountants
* This exhibit represents a management contract or a compensatory plan